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CHAPTER I
INTRODUCTION

Metastasis is believed to involve a series of sequential
events

which

include

intravasation,

extravasation

and

invasion, during which tumor cells must penetrate various host
tissue barriers.

This has led to a hypothesis that metastasis

may require the enzymatic degradation of structural components
of the extracellular matrix and basement membrane.

Consistent

with this hypothesis, many studies have shown increased levels
of proteolytic enzymes produced by tumor cells.

These include

metalloproteinases such as collagenase (Fessler et al. 1984),
serine proteinases such as tissue type and urokinase type
plasminogen activators (Moscatelli et al. 1980; Schmitt et al.
1992), and several lysosomal proteinases including cathepsin
B (Sloane et al.
1984; Qian et al.

1981; Recklies et al.
1989;) ,

cathepsin L

1982; Dufek et al.
(Gal and Gottesman,

1986; Troen et al. 1988) and cathepsin D (Capony et al. 1987;
Maudelonde et al. 1988).
Among these proteinases which may play a role in the
metastatic

process,

investigated.

cathepsin

B

has

been

extensively

Cathepsin B is capable of degrading many of the

protein constituents in the extracellular matrix,

such as

f ibronectin, laminin, and type IV collagen and others (Sloane,
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1990; Delaisse et al. 1991; Buck et al. 1992; Cardozo et al.
1992) .

Cathepsin B can also activate a

number of latent

extracellular proteinases such as procollagenase (Eeckhout and
Vaes,

1977)

and proplasminogen activator

1991; Schmitt et al. 1992).

(Kobayashi et al.

Consequently, were cathepsin B to

be secreted by tumor cells, it could cause the degradation of
the structural barriers through which tumor cells must migrate
during invasion and metastasis (Docherty et al. 1983).
Elevated levels of cathepsin B are often associated
with cancer (Sloane, 1990).

In addition, cathepsin Bis not

exclusively targeted to lysosomes in tumor cells.
reported to be in the nucleus

It has been

(Pietras and Roberts,

1981)

where it could act to modify proteins which regulate DNA
replication and gene expression.

Cell surface and secreted

forms of cathepsin B are also well documented in malignant
tumors. In rodents, levels of intracellular and secreted forms
of cathepsin B have been correlated with metastatic potential
in murine B16 melanoma variants (Sloane et al. 1981; Sloane et

al.

1982;

Qian et al.

1989),

in BOX rat sarcoma variants

(Koppel et al. 1984) and Lewis lung tumors (Takenaga, 1984),
and in humans,

(Ohsawa et al.

in liver

1989),

colorectal

(Keppler et al. 1988a; Maciewicz et al. 1989; Sheahan et al.
1989),

gastric

(Watanabe

(Kasafirek et al. 1990).

et

al.

1989)

and

lung

tumors

Higher molecular weight latent forms

of cathepsin B have been detected in body fluids of patients
with primary liver cancer, ovarian cancer (Mort et al. 1983;

3

Dufek et al. 1984) and breast cancer {Petrova-Skalkova et al.
1987).

Forms of cathepsin B associated with the cell surface

have been reported for human, rat, and murine tumors {Recklies

et al. 1982; Mort et al. 1983; Koppel et al. 1984; Dufek et
al.

1984; Petrova-Skalkova et al.

1987; Keren and LeGrue,

1988), and have been correlated with tumor invasiveness and/or
metastasis in humans {Weiss et al. 1990) and rodents {Sloane

et al. 1986). These and similar findings suggest a direct or
indirect role for cathepsin B in facilitating tumor metastasis
through its ability to degrade the extracellular matrix and to
release tumor cells from solid tumors.

However the molecular

basis for the increased production of cathepsin B and its
abnormal localization to cell membranes, nuclei and secretory
vesicles of tumor cells is unknown.
Eukaryotic

pre-mRNAs

processing events.

undergo

a

series

of

nuclear

Splicing of all intron sequences must

occur with a high degree of accuracy in order for functional
proteins

to

be

generated.

However,

flexibility

in

the

selection of a splice site, which forms the basis for. the
alternative splicing, is not unexpected.

Alternative splicing

can produce different but related messages.

The variant

proteins derived from these messages could then be targeted to
different cellular and subcellular locations {Kwiatkowski et

al. 1986; Johnson et al. 1990; Alt et al. 1980).

Alternative

splicing can also produce messages which vary in their 5 1 - or
3 1 -untranslated regions {UTRs) and consequently affect mRNA

4

stability

and

Brawerman,

translational

1987) .

Thus,

efficiency

alternative

(Kozak,

1991a,b;

processing

of

the

cathepsin B pre-mRNA may be one of many possible factors which
can be advanced for differences in cathepsin B protein levels
between normal tissues and tumors, and for the presence of
unusual tumor forms of cathepsin B protein which might be
directed

to

the

nucleus,

the

cell

B

cloned

surface

or

the

cell

exterior.
Cathepsin

mRNA

from

human

kidney

is

heterogeneous due to alternative processing of the 5 ' - and 3 ' ends of the primary transcript,

resulting

in mRNAs which

contain alternative 5'- and 3 1 -UTRs (Gong et al. 1993).

The

variable removal of exon 2 produces transcripts which differ
by 88 bases in the lengths of their 5'-UTR.

The sequence of

exon 2 has features which could decrease the translational
efficiency of the transcript.

Consequently, were exon 2 more

frequently absent from the 5'-UTR of tumor cell cathepsin B
mRNAs,
tumors.

it could explain higher

levels

of

cathepsin B in

In this present work we have found that some human

tumors contain a third class of transcripts which lack exon 3.
As exon 3 contains the coding sequence for the signal peptide
required to initially direct cathepsin B to lysosomes, and a
portion of the inhibitory propeptide,

mRNA lacking exon 3

could be responsible for the presence of active cathepsin B
forms at the cell surface and/or within the nuclei of human
tumors.

5

It is my hypothesis that the higher levels of cathepsin
B found in tumor cells is due to differences in cathepsin B
pre-mRNA processing between normal tissues and tumor cells.
Therefore, the specific aims of the present research are: 1)
to

determine

relative

abundances

of

different mRNA

forms

between normal human tissues and human tumors; 2) to determine
translational activities of the various cathepsin B mRNAs
which differ in the length of their 5'-UTRs in an in vitro
translation assay; 3) to clone the transcript lacking exon 3
and to study its translational potential in an in vitro assay
system;

and 4)

to determine whether

the putative protein

products of messages which lack exon 3 possess peptidolytic
activity.

CHAPTER I I

REVIEW OP THE RELATED LITERATURE

A.

Cellular Proteinases

Proteases include two groups: exopeptidase (peptidases)
which cleave either amino- or carboxyl-terminal amino acids or
dipeptides from proteins,
which

cleave

molecules.

peptide

and endopeptidases

bonds

in

the

(proteinases)

interior

of

However, some proteases can have both

protein
exo- and

endo-peptidase activities.
Proteases can also be subdivided into five classes based
on the mechanisms of peptide bond cleavage catalyzed by their
active center (Barrett, 1980a): serine proteinases, cysteine
proteinases, aspartic proteinases, metalloproteinases, and a
fifth

category

which

includes

enzymes

undetermined catalytic mechanisms.

with

different

or

Each of the first four

classes will be briefly discussed, and then cathepsin B will
be introduced.
1. serine Proteinases

Serine

proteinases

include

trypsin,

chymotrypsin,

elastase, coagulation factors, plasmin, cathepsin G, chymases,
tryptases,

plasminogen

activators
6

and

others.

Sequence

7

homologies among the serine proteinases suggest that they may
have a common evolutionary origin (Hartley,

1970).

Serine

proteinases all have a serine in their active sites and are
active at neutral pH without the need of cofactors.

An

adjacent histidine residue which functions as a general acidgeneral base catalyst is essential for the activity of these
enzymes

(Walsh,

1979).

They are synthesized as

inactive

processors that require limited proteolysis for activation.
Serine proteinases,

which participate

in coagulation,

are

controlled by a cascade of activating enzymes and a system of
protein proteinase inhibitors.

Serine proteinases that have

been of particular interest in cancer metastasis are plasmin
and the pro-urokinase and tissue type plasminogen activators.

2. cysteine Proteinases
Cysteine proteinases contain a cysteine residue in their
active sites.

An adjacent histidine residue which functions

as a general acid-general base catalyst is also essential for
the activity of this class of enzymes {Topham et al. 1990).
This

subclass

of

proteinases

includes

lysosomal

enzymes

(cathepsin B, Hand L) (Barrett, 1980b), the plant proteinase
papain,

and

the

proteinases,

calpains

Schollmeyer, 1981).
cathepsin
homologous
papain

B

cytosolic

and

(Barth

calcium-activated
and

H have

more

1981;

Dayton

and

The amino acid sequence of papain and of
been

(Takio et al. 1983) .

appear

Elce,

neutral

closely

found

to

However,

related

than

be

significantly

cathepsin H and
are

papain

and

8

cathepsin B or cathepsin H and cathepsin B.

The active sites

of cathepsin B and papain are functionally homologous as well
as structurally homologous (Bajkowski and Frankfater, 1983a;
Bajkowski and Frankfater,

The lysosomal cysteine

1983b) .

proteinases are synthesized as

larger

which undergo proteolytic maturation.

inactive precursors

Their mature forms are

normally confined to the lysosome and thought to play an
important role in intracellular protein degradation.

The

lysosomal cysteine proteinases exhibit pH optima of about 6. O,
and are unstable above pH 7
Barrett, 1984).
such

as

(Barrett and Kirschke,

1981;

However, some lysosomal cysteine proteinases,

cathepsin

B,

are

secreted

into

extracellular

environment by tumor cells, and appear to retain activity at
and above pH 7.0 (Mullins and Rohrlich, 1983).
3. Aspartic Proteinases

Members of the family of aspartic proteinases include
pepsin, renin and cathepsin D.
aspartate
inactive

in

their

precursors

autocatalytically
renin)

active

(e.g.

All of these enzymes contain

sites,

which
pepsin)

and
are

are

synthesized

processed

or by other enzymes

to remove an N-terminal propeptide.

Pepsin,

as

either
(e.g.

which

functions in the acidic milieu of the stomach, is responsible
for the initial steps in protein digestion.

cathepsin D is a

lysosomal enzyme and plays an important role in intracellular
proteolysis in the acidic environment of the lysosome.

Renin

is thought to have originated from the hypothetical cathepsin

9

D-like archetype.

However, unlike cathepsin D it is stable

and active at neutral pH, and is highly specific for the LeuLeu bond that generates angiotensin I

from angiotensinogen

(Reid et al. 1978).

4. Metalloproteinases
Metalloproteinases are characterized by the presence of
zn2+ in their active sites.

Examples of this group include

pancreatic carboxypeptidase,

thermolysin and collagenases.

The metalloproteinases have a neutral to slightly alkaline pH
optimum, and their activities can be inhibited by EDTA and
thiols.

They seem well suited to function extracellularly.

Type IV collagenase, a metalloproteinase, has been found
to be secreted by a variety of malignant tumors (Liotta et al.
1982; Fessler et al. 1984).

The type IV collagenase degrades

the basement membrane type IV collagen molecule at a single
site in the helical domain at about one fourth the distance
from the N-terminal end (Fessler et al. 1984).

Accordingly,

the enzyme may be able to decompose the collagen network of
basement membrane and thus facilitates penetration by tumor
cells.

B.

cathepsin B
Cathepsin B is a

cysteine proteinase

lysosomes of mammalian cells.

located

in the

Cathepsin B has been isolated

from tissues of various mammalian species, including rat liver
(Otto, 1971), bovine spleen and liver (Otto, 1971), and human

10
spleen

and

methods,

liver

(Barrett,

cathepsin B has

1973).

been

Using

immunochemical

located within macrophages

(Howie et al. 1985), fibroblasts (Mort et al. 1981), neurons
(Howie

et

al.

1985),

myocytes

(Howie et al.

epithelial cells

et

(Bird
1985)

al.

1985)

and

of various tissues.

Cathepsin B is thought to play an important role in a number
of

physiological

and

pathological

processes

including:

(Huisman et al.

degradation of endocytosed proteins

1974;

Bystryn and Perlstein, 1982) and intracellular proteins (Kar
and

Pearson,

1977;

Shaw

and

Dean,

1980);

processing

of

secreted proteins (Quinn and Judah, 1978), enzymes (Figarella

et

al.

1988) ,

hormones

(Docherty

neuromodulatory polypeptides

and

Steiner,

1982)

(Docherty and Steiner,

tissue resorption and remodeling

(Bayliss and Ali,

and

1982) ;
1978) ;

inflammation (Daries et al. 1978) and mediation of hormonal
response (Pietras et al. 1975).

At present, the full spectrum

of the biological role of cathepsin B is still not very clear
but

its

broad tissue distribution suggests

it has many

important functions.
Cathepsin B is both an endopeptidase and a
dipeptidase
cathepsin

(Aronson

B is

catalyzing the

an

and

Barrett,

exopeptidase

1978).

(Polgar

successive removal

of

peptidyl

Below

and Csoma,

dipeptides

pH

1987)

from

carboxyl terminus of proteins (Aronson and Barrett,

5,

the

1978).

Between pH 5 and 7, cathepsin B shows endopeptidase activity
(Polgar and Csoma, 1987) with a broad specificity (Barrett and

11
Kirschke, 1981; Mason, 1989).
the

-Arg-Arg-

sequence,

Synthetic substrates containing
such

as

Benzoyl-L-arginine-L-

arginine-2-naphthylamide, are extremely sensitive to cathepsin
B (McDonald and Ellis, 1975).

Fluorogenic and chromogenic

synthetic substrates are the most common substrates used in
enzyme

assays

for

determination

of

cathepsin

B activity

(Barrett, 1973; Bajkowski and Frankfater, 1975).
Mature cathepsin B has a molecular weight of 27,000 29,000.

It is derived from a larger precursor, procathepsin

B, which in its glycosylated state has a molecular weight of
about

43,000

(Barrett,

1987;

Nishimura

et

al.

1988).

Proteolytic processing of the precursor yields both an active
single chain form and a two chain form
1987).

(Hanewinkel et al.

Procathepsin B can also be activated in vitro by

limited proteolytic cleavage with pepsin (Achkar et al. 1990;
Rowan et al. 1992).
preprocathepsin

B

Procathepsin Bis in turn derived from
which

endoplasmic reticulum.

is

synthesized

on

the

rough

Preprocathepsin B is converted to

procathepsin B by cleavage with a

signal peptidase which

removes the N-terminal signal peptide in the lumen of the
rough endoplasmic reticulum.
Procathepsin B is directed to the lysosome where it is
converted to biologically active mature forms (McDonald and
Ellis, 1975).

In fibroblasts,

phosphate receptors

it is known that mannose-6-

segregate newly

synthesized

lysosomal

enzymes from secretory proteins in the trans Golgi network.
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The

lysosomal

enzyme-receptor complex

is

delivered to an

intermediate acidified compartment where dissociation of the
complex occurs.

Receptors are then returned to the Golgi

apparatus and cell surf ace for reuse while lysosomal enzymes
in turn are transferred to the lysosome.
There

have

been

many

reports

of

cathepsin

B-like

activities associated with polypeptides of Mr greater than
26, 000-27, ooo.

Steiner and coworkers have shown that

tyrosyl-Arg-ArgCH2Cl,

a

cathepsin

B

substrate

125

I-

analog,

covalently labeled three polypeptides of Mr 39, 000, 31, 500 and
25,000 in rat islet cells

(Docherty et al.

1983)

and in a

transplantable rat insulinoma (Docherty et al. 1984).

The Mr

= 31,500 form cross-reacted with anti-rat liver cathepsin B

antibodies.

Pepsin

treatment

of

the

Mr

=

39, 000

form

converted it to a 31,500 protein which was also precipitated
with anti-rat liver cathepsin B antibodies, suggesting that
the 39,000 and 31,500 polypeptides are related as precursor to
product.

These workers also found that cathepsin B in rat

islets is synthesized initially as a precursor of approximate
Mr= 43,000.

In the insulinoma the Mr= 39,000 form was found

in insulin secretory granules, the Mr = 31,500 form was found
in secretory granules and lysosomes, whereas the Mr = 25,000
species

was

only

found

in

the

lysosomal

fraction.

Consequently, it has been suggested that the larger percursor
farms of cathepsin B are sorted into secretory granules,
possibly as a consequence of their incomplete targeting to
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lysosomes via the mannose-6-phosphate pathway.
Preprocathepsin B cDNAs of human (Fong et al. 1986), rat
(Chan et al.

1986)

and mouse (Fong et al.

cloned and sequenced.
339 amino acids.

1986) have been

Each predicts a primary structure of

The amino acid sequences of the rat and

mouse enzymes are similar, with 90% identity.

The human and

rat amino sequences are 84% identical in the regions of the
mature proteins, and about 50% identical in the preproregions
and c-terminal peptide extensions.
The entire human cathepsin B gene has been cloned and its
structure

elucidated.

The

350

nucleotides

preceding

the

transcription start site, large portions of introns 1 and 2
(Gong et al. 1993), and all 12 exons have been sequenced (Fong

et al. 1986).

There are several Spl binding sites in the S'-

flanking region and in intron 1 but no TATA box appropriately
positioned with respect to the transcription initiation site.
Cathepsin

B

cDNA

cloned

from

human

tissues

is

heterogeneous due to differences in processing of the 5' and
3'-ends of the pre-mRNA (Figure 1).

Alternative splicing,

"exon 2 skipping", produces mRNAs which differ by 88 bases in
the lengths of their 5 1 -untranslated regions.

The occasional

selection of an alternative intron donor site in exon 11 can
result in the loss of an adjacent polyadenylation signal in
exon 11 and termination after a downstream signal in exon 12.
This produces two kinds of transcripts (2. 3Kb and 4. OKb) which
vary in the lengths of their 3'-untranslated regions.
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Figure 1.
Organization of the cathepsin B gene and its mRNA transcript. Intron
positions (f) and polyadenylation signals (A) are identified. The coding regions for
the prepeptide, activation propeptide and mature enzyme are indicated by boxes. Also
shown are the sizes of the first six exons.
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The mouse cathepsin B gene and its 5 '-upstream region has
also been cloned (Qian et al. 1991b).
and 9 introns spanning about 20 kb.

The gene has 10 exons
Exon 10 contains three

potential polyadenylation sites which are alternatively used
in transcription

of cathepsin B mRNA in B16 melanoma.

Like

that of human cathepsin B, the 5 1 upstream region of the mouse
cathepsin B gene has several Spl binding sites and lacks a
TATA box in the immediate vicinity of the transcription start
site (Qian et al. 1991b).

c.

correlation Between cathepsin B Expression and Malignant
Tumors
Sufficient

evidence

has

accumulated

to

implicate

proteolytic enzymes as playing an important role in tumor
metastasis.

Proteinases,

either

on

the

cell

surface

or

released by tumor cells, are thought to facilitate tumor cell
colonization (Yee and Shiu, 1980; Mainferme et al.

1985) .

Consequently, many studies have focused on enzymes that are
known to degrade connective tissue constituents,
collagenase

(Liotta

et

al.

1979),

neutral

such as

proteinase

(Edmonds-Alt et al. 1980), plasminogen activator (Laug et al.
1983) ,

glycosidase

(Kramer et al.

1986)

(Recklies et al. 1982; Qian et al. 1989).

and cathepsin B
There may also

exist a proteolytic cascade in which one or more proteinases
act in concert and a newly activated protein in turn may
activate others (Kramer et al. 1986; Kobayashi et al. 1992).
In the case of cathepsin B, increased enzyme activity has
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been found in a large number of .metastatic tumors.

Elevated

cathepsin B activity has been reported in humans for liver
(Dufek et al. 1985), colorectal (Dufek et al. 1984; Keppler et

al.

1988a;

Maciewicz

et al.

1989;

Sheahan et al.

1989),

gastric (Watanabe et al. 1989), breast (Poole et al. 1978;
Recklies et al. 1980; Dengler et al. 1991; Lah et al. 1992),
lung (Kasafirek et al. 1990) and cervical cancers (Pietras and
Roberts, 1981).

In addition, positive correlations have been

observed between intracellular levels of cathepsin B and the
metastatic phenotype

in the murine B16

melanoma variants

(Sloane et al. 1981; Sloane et al. 1982), in cultured three
Lewis lung clones (Takenaga, 1984) and in cultured BDX rat
sarcoma variants (Koppel et al. 1984).

The presence of the

elevated cathepsin B activity in tumor cells suggests a direct
or indirect role for this enzyme in the degradation of the
extracellular matrix and in the release of tumor cells from
solid tumors.

cathepsin B can degrade fibronectin,

laminin

and type IV collagen (Sloane, 1990), and can activate latent
collagenase (Eeckhout and Vaes, 1977) and pro-urokinase type
plasminogen activator (Kobayashi et al. 1991).
Further evidence in support of a role for cathepsin B in
tumor invasion is the observation of increased cathepsin B
activity in plasma membrane of tumor cells, at the margins of
actively

growing

tumors

in

direct

contact

with

the

extracellular matrix, and the observation of the release of
cathepsin B from tumor cells.

Cathepsin B

act~vity

has been
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found in the plasma membrane fraction from anaplastic sarcoma
(Koppel et al. 1984}, from murine fibrosarcomas

in BOX rat

(Keren and LeGrue, 1988}, from mouse B16 melanoma variants in
proportion to the metastatic potential of the variants (Sloane
et al.

1986},

and from a

(Zucker et al. 1985}.

human pancreatic adenocarcinoma

Cathepsin B activity is localized at

the invasion front of a rabbit V2 carcinoma
1981}.

(Graf et al.

The secreted enzymes are very similar to lysosomal

cathepsin

B

substrates.

in

terms

of

their

reactivity

to

synthetic

It was shown that cultured explants of malignant

human breast tumors released eleven times more cathepsin B
activity than normal breast tissue or nonmalignant tumors
(Poole et al.

1978; Recklies et al.

1980).

Other reports

indicated elevation of cathepsin B activity in the serum of
women with genital tract cancer especially in those patients
with invasive carcinomas

(Pietras et al. 1979; Pietras and

Roberts, 1981}, in malignant ascites fluid from patients with
primary liver and ovarian cancer ( Mort et al. 1983; Dufek et

al.

1984) ,

cancer

in pleural effusions from patients with breast

(Petrova-Skalkova et al.

1987),

and in conditioned

media from human and murine tumors (Recklies et al. 1982; Mort

et al. 1983; Qian et al. 1989).
The

secreted

cathepsin

B-like

enzyme

activities

are

different from lysosomal cathepsin B in that they have higher
molecular weights.

Two extracellular high molecular weight

forms of human cathepsin B with Mr 40,000 have been observed,
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one is latent, the other active. In ascitic fluid and culture
medium of ascites cells from cancer patients, a latent form of
cathepsin B was discovered which could be activated by pepsin
pretreatment (Mort et al. 1981).

In addition, malignant human

breast tumors in organ culture release a high molecular weight
form of cathepsin B that was detected by

its ability to

hydrolyze synthetic substrates for which lysosomal cathepsin
B has high specificity (Mort et al. 1980).

The advantages

that tumor cells gain by secreting latent and high molecular
weight forms of lysosomal proteinase may be related to the
instability of low molecular weight lysosomal form above pH 7,
resulting in rapid denaturation and inactivation in serum.

In

contrast, high molecular weight latent and active forms of
cathepsin B are more stable under these same conditions (Mort
In addition,

secretion of a

latent

and Rechlies,

1986).

enzyme,

is then activated some distance from tumor

which

cells, may protect the enzyme from inactivation by endogenous
inhibitor while undergoing transport to its site of action.
Thus,

the active,

high molecular weight secreted form of

cathepsin B is not inhibi table by plasma proteinase inhibitor,
a2-macroglobulin, whereas the lysosomal form is inhibitable
(Mort and Rechlies, 1986).

Schultz and his associates found

that leupeptin, an inhibitor of cathepsin B did not prevent
the

invasion

of

B16-F10

melanoma

cells

across

basement

membrane in vitro (Persky et al. 1986) or lung colonization in

vivo (Ostrowski et al.

1986).

In contrast,

Belleli et al
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(1990)

recently found that papain-inununized mice possessed

serum antibodies which

cross-react with

cathepsin B like

endopeptidase isolated from B16 melanoma cells.

The growth

rate, invasion and metastasis of both B16 melanoma and the
Lewis lung carcinoma were inhibited in mice immunized with
papain.

It

may

be

that

the

secreted

and/or

membrane

associated forms of cathepsin B, which might be insensitive to
inhibition

by

leupeptin

but

can

react

with

anti-papain

antibodies,

play a role in the metastasis of B16 melanoma

cells.
The molecular basis for increased cellular and secreted
levels and altered cellular distribution of cathepsin B in
Possible factors may

tumor cells is not well understood.
include differences

in transcription,

post-transcriptional

processing, translation, and post-translational processing of
cathepsin B.
proteinases,
cells,
tissues

Comparisons of mRNA levels for five lysosomal
cathepsin B,

D,

H,

L,

and S in B16 melanoma

in rat W-256 carcinoma cells,
revealed

that

only

the

mRNA

and in normal rodent
for

cathepsin

B is

elevated in the malignant tumors (Qian et al. 1989; Qian et

al. 1990).

A correlation between the metastatic potentials of

several B16 melanoma variants and cathepsin B mRNA levels has
been observed.

No evidence was found for gene amplification

or gross chromosome rearrangement, or for the presence of more
than one gene for

cathepsin B in melanoma cells.

These

findings together with recent results of nuclear run off
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assays (F. Qian, unpublished results)

suggest that in these

cells cathepsin B expression is regulated, at least in part,
at the level of RNA transcription.
In addition to the normal 2.2 Kb transcript, two larger
transcripts

( 4. o and 5. o Kb) were found in B16 melanomas.

These larger transcripts were not seen in normal mouse tissues
(Qian et al. 1989).

A comparison of the cDNAs derived from

the larger transcripts with the cathepsin B gene and cDNA
derived

from

normal

message

revealed

that

all

three

transcripts from mouse melanoma cells encoded for the same
form of cathepsin B and differed only in the lengths of their
3 1 -untranslated regions.

The differences in the 3'-UTRs was

due to the utilization of alternative polyadenylation signals
during the processing of the 3'-end of cathepsin B pre-mRNA,
the larger transcripts resulting from the occassional use of
downstream polyadenylation signals in melanoma cells (Qian et

al.

199lb;

Qian et al.

1991c) •

Thus,

the secretion and

altered distribution of cathepsin B in murine melanoma cells
is not due to alteration in the gene or
processing,

but

more

likely

due

to

in the pre-mRNA

aberrant

proenzyme

processing and sorting.
Mannose-6-phosphate receptors and mannose-6-phosphatecontaining sugar side chains are required for correct delivery
of enzymes to lysosomes (Kornfeld, 1987).

Alterations in N-

linked oligosaccharides have been found in proprecathepsin D
secreted by MCF7 mammary cancer cells (Capony et al. 1989).
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The secretion of procathepsin L by Kirsten sarcoma virustransformed fibroblasts {KNIH cell) is reported to be due to
poor binding of cathepsin L to mannose-6-phosphate receptor,
together with saturation of the mannose-6-phosphate receptor
resulting from cathepsin L overexpression {Dong et al. 1989).
Moloney murine sarcoma virus-transformed fibroblasts

{MMSV

cell) express 3-4 fold higher levels of cathepsins B, D, and
L, but not Hand S {Qian et al. 199la).

In addition, MMSV

cells appear to have a general defect in lysosomal enzyme
sorting

which

causes

the

increased

cathepsin B, cathepsin L and an active

et al. 1990).

secretion

of

latent

~-glucuronidase

(Achkar

This enhanced lysosomal enzyme secretion was

correlated with an absence of cell surf ace mannose-6-phosphate
receptor activity (Achkar et al. 1990) and an alkalinization
of

vacuolar

compartments,

which

should

prevent

lysosomal

enzyme-mannose-6-phosphate receptor uncoupling (Pracht et al.
1991).

Agents which acidified MMSV cells strongly inhibited

cathepsin B secretion and restored cellular levels to amounts
seen in normal fibroblasts.

These results agree with the

finding that estrogen increases the secretion of cathepsins D,
L,

and B by human mammary carcinoma MCF-7 cells by down-

regulating mannose-6-phosphate receptor expression (Mathieu et

al. 1991) .
In contrast to the above results in mouse, cathepsin B
expression in human tissues may be regulated at the level of
mRNA processing.

Multiple forms of the cathepsin B mRNAs
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which differ in their 3 1 and s•-untranslated regions were also
found in human tissues.
from

alternative

These different forms of mRNA arise

splicing

regions (Figure 1).

of

the

5'

and

3 '-untranslated

Examples of messages with alternative 5 '-

untranslated regions have been described (Young et al. 1981;
Lowe et al.

1987;

Shen et al.

Nonaka et al.

1988;

Horiuchi et al. 1990; Waterhouse et al. 1990).

1989;

Many reports

have indicated that changes in the s•-noncoding sequence of a
message can affect the translational efficiency of the message
(Rao et al.

1988; Horiuchi et al.

1990; Grens and Scheffler, 1990).

1990; Waterhouse et al.

Alternative utilization of

multiple polyadenylation signals in 3'-end processing of premRNA has also been described (Setzer et al. 1980; Tosi et al.
1981; Aho et al. 1983;
the

3'-ends

of

Sanke et al. 1988).

messages

have

been

shown

Modifications at
to

affect

the

translational capacity (Grens and Scheffler, 1990) and rates
of mRNA turnover (Brawerman, 1987; Ross, 1988) in some cases.
The

alternative

splicing

of

pre-mRNA

and

its

functional

effects are reviewed in next section.

D.

Alternative Pre-mRNA Splicing
Eukaryotic pre-messenger RNAs undergo a series of nuclear

processing events.

In addition to S' capping with 7-methyl

guanosine (Salditt-Georgieff et al. 1980), and the addition of
a

poly A tail

to

the

3'

end of the nascent

transcripts

(Birnstiel et al. 1985), introns must be precisely excised and
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exons correctly ligated to avoid disrupting the open reading
frame.

Not unexpectedly,

the pre-mRNAs can sometimes be

spliced in more than one way.
pre-mRNA

splicing

has

In recent years, alterative

emerged

as

a

powerful

post-

transcriptional mechanism for regulating gene expression.

By

utilizing different splice sites within the same precursor
RNA, multiple transcripts and corresponding protein products
can be generated from

a

single gene.

In

this

section,

alternative splicing and its function will be reviewed after
briefly introducing constitutive splicing.
1. Constitutive Splicing

The splicing reaction has been extensively studied in
cell-free systems that used exogenous pre-mRNA substrates
(Grabowski et al. 1984; Krainer et al. 1984; Ruskin et al.
1984

Lambowitz,

1989).

Splicing

is

a

multistep

process

involving two successive transesterification reactions (Sharp,
1987).

Initially,

cleavage occurs at the 5'

donor splice

site, and the 5' end of the intron is joined to an adenosine
residue located within the intron (branch-point), giving rise
to

a

lariat

form

of

the

intron.

The

second

transesterification reaction between the 5 1 splice donor and

J' splice acceptor sites results in ligation of the exons and
release of the lariat intron.

Comparison of sequences of the

corresponding genomic DNA with that of cDNA revealed that
moderately conserved and short consensus sequences exist at
intron-exon boundaries (Mount,

1982).

The 5 1 donor splice
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site consensus is AG/GUPuGU (where the intron-exon boundary is
denoted by the backslash), and the 3' acceptor splice site
consensus sequence is P.yAG/G.

Of these bases, the most highly

conserved are the first two and last two bases of the intron.
Al though important,

these consensus sequences are not

sufficient to define efficient splice sites because similar
sequences are found in positions other than actual splice
sites.

Some of these cryptic sites can be activated when the

normal splice sites are mutated ( Ruskin et al. 1985; Aebi et

al. 1987).

Several observations had led to a suggestion that

small ribonucleoprotein particles (snRNPs) somehow assisted in
the splicing reaction.

First, the short consensus sequence at

the 5' end of introns was found to be complementary to a site
near the 5' end of the small nuclear RNA (snRNA), called Ul
(Lerner et al. 1980).
extracts as part of

Second, snRNAs were found in nuclear
large

(Steitz et al. 1988).

particles containing pre-mRNA

Subsequently, Ul, U2, U4, US and U6

have been purified, sequenced and shown to be necessary for
splicing

(Guthrie,

1991; Ruby and Abelson,

1991).

All of

these snRNAs are associated in the nucleus with six to ten
proteins to form snRNPs.

These snRNPs assemble with pre-mRNA

and additional proteins to form a large particle, called a
spliceosome.
The total population of pre-mRNA in the cell nucleus,
known

as

heterogeneous

nuclear

RNA

(hnRNA),

is

found

in

association with a discrete set of proteins, forming repeating
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structures termed hnRNP particles.

These are visualized as a

linear array of globular monoparticles along each pre-mRNA
molecule

(Dreyfuss,

1986).

Cleavage of the linker RNA by

brief RNase treatment releases single particles that sediment
at 30-405.

These particles contain a segment of hnRNA about

700 nucleotides long and core hnRNP proteins, Al, A2, Bl, B2,
Cl, and C2,
1988).

in a well-defined stoichiometry (Conway et al.

Because of their abundance and association with hnRNA,

hnRNP proteins are thought to be involved in the packing and
posttranscriptional processing of all pre-mRNA.

In vitro

studies under splicing conditions showed sequence-specific
binding of hnRNP protein Al to the 3' splicing site (Swanson
and Dreyfuss, 1988).

In nuclear extracts, UV-induced cross-

linking of hnRNP proteins Al and C to pre-mRNA requires the
presence

of

Ul

and

U2

snRNPs,

suggesting

interaction take place between hnRNP
(Mayrand and Pederson, 1990).

and

that

specific

snRNP particles

Prevention of in vitro splicing

reaction by the antibodies against hnRNP proteins indicated a
requirement of hnRNP proteins during splicing (Choi et al.
1986; Sierakowska et al. 1986).
The interactions of the cis-acting elements in pre-mRNA
with the trans-acting protein and snRNA factors are necessary
for constitutive splicing.

These interactions are thought to

be altered and/or regulated to allow for alternative splicing.
2. Modes of Alternative Splicing

Smith et al (1989) have devised a scheme for classifying
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alternative splicing based upon a wide variety of possible
regulated

events

which

can

give

rise

to

different

mRNA

transcripts from the same initial gene.
Retained Intron

Introns can either be spliced out or

retained in the mature RNA.

The retained intron can result in

a premature termination, an altered amino acid segment due to
frameshift, or the insertion of a peptide if the open reading
frame is maintained.
cause

functionally

Premature termination or frameshift may
different products

produce no functional product.

to

be made

or may

Such examples are found in the

genes for fibronectin (Schwarzbauer et al. 1987) and the Achain of platelet derived growth factor (Tong et al. 1987).
Alternative

s•

Donor

Sites

and
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Acceptor

Sites

Alternative utilization of 5' donor and/or 3' acceptor sites
can excise introns of different lengths, resulting in retained
exons of different sizes.

Again, this can give rise to the

insertion or deletion of a small peptide if the reading frame
is maintained, or frameshifting and premature termination.
Alternative Promoters and Polyadenylation Sites

In some

cases, a gene may contain more than one promoter or more than
one poly A attachment site.

The mRNAs which differ in their

5 1 and 3' ends can result from differential utilization of
more

than

signal.

one
This

promoter

or more

can

to variations

lead

than

one
in

polyadenylation
the

amino

acid

sequence of the amino- or carboxyl-terminals of a protein, or
to variations in the 5 1 and 3 1 untranslated regions of the
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message.

Utilization of alternative promoters dictates the

splicing pattern of myosin light chain gene (Periasamy et al.
1984), while an example of alternative 3 1 end exons resulting
from the selection of different polyadenylation sites is found
in a-tropomyosin transcripts (Helfman et al. 1986).
Internal exons are sometimes

Mutually Exclusive Exons

used in a mutually exclusive manner.

One member of the pair

is always spliced into the mRNA, but never both.
two exons
skipped.
and~

are never spliced together,

nor

Thus, the

are they both

Examples of such splicing are found in genes for a

tropomyosins (Helfman et al. 1986; Goodwin et al. 1991).

Isof orms

TM-Sa

and

TM-Sb

of

a-tropomyosin

are

due

alternative inclusion of exon Ga and 6b respectively.
differences

in

alternate exons

the

amino-acid

affects

the

sequence

encoded

by

to
The

these

act in-binding pattern of

the

tropomyosin.
Cassette Exons

excluded

(skipped} .

Some cassette exons can be included or
This can lead to insertion of small

peptide segment, premature termination, or a shift of reading
frame.

An example of such cassette exons is found in the

troponin-T gene

(Breitbart and

Nadal-Ginard,

1987).

The

presence of five cassette exons at S' end of the gene give
rise to hypervariability within the

N-terminal

region

of

troponin-T.
3. Factors Affecting Splicing-site Selection

Splicing of all intron-containing pre-mRNAs must occur
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precisely in order to generate functional proteins.
splicing

sites,

accurately

which

selected

mechanisms.

exhibit
and

sequence

matched

by

Authentic

conservation,
poorly

are

understood

On the other hand, flexibility in the selection

of splice sites forms the basis for alternative splicing, an
important mechanism for posttranscriptional control of gene
expression.

Thus, a large number of genes ·can express several

related, but structurally and functionally distinct protein
isoforms.

The corresponding mRNAs arise by selection of

alternative splice sites, a process that is often subject to
tissue-specific

or

developmental

control.

The

molecular

mechanisms responsible for the specificity of constitutive and
alternative splice-site selection are not well understood.
Some cis- and trans-acting factors have been reported to be
involved

in

splice-site

selection,

some

essential

for

splicing, others affecting the efficiency with which a splice
site is utilized.

RNA secondary structure is also shown to

affect splice-site selection.
Cis-Actinq Factors

The 5' splice site acting as a cis-

splicing element is highly conserved (Ohshima and Gotoh, 1987;
Shapiro and Senapathy,

1987).

Mutations within the 5'

GU

dinucleotide at the intron boundary inhibit in vitro splicing
(Aebi et al.

1987;

Treiman et al.

1983),

and often cause

activation of nearby cryptic splice sites in vivo.
of the 5'

Variations

splice-site consensus outside of the GU do not

absolutely impair splicing, but can affect the efficiency with
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which the splice-site is used.
sites

towards

the

Usually, mutation of 5' splice

consensus

improves

their

competitive

efficiency {Aebi et al. 1986; Eperon et al. 1986; Zhuang et

al. 1987; Mayeda and Ohshima, 1988).
The 3 ' splice-site consensus is another cis-acting factor
which can affect the splicing.

The AG dinucleotide at the

intron-exon boundary is absolutely conserved
Padgett et al.

1986; Ohshima and Gotoh,

{Mount,

1987).

1982;

The point

mutation or deletion of the AG dinucleotide always inhibits
splicing to the mutated splice site {Aebi et al. 1986; Lamond

et al. 1987).

However,

in some cases, this mutation could

result in utilization of the next downstream AG dinucleotide
as the 3 1 splice site.
In addition to 5 1 and 3 1 splice site consensus,

branch-

point sequence and location have also been shown to affect the
splicing.

The branch-point consensus is commonly found 20-40

nt upstream of the 3 1 splice site {Smith and Nadal-Ginard,
1989; Helfman and Ricci,

1989).

Deletion

of the sequence

between the branch-point and 3' splice site could result in
alternative splice-site selection { Helfman et al. 1990; Guo

et al.

1991).

The most highly conserved position in the

consensus is the A at the site of branch formation.

Point

mutations of the branch-point sequence often have no effect
upon splicing due to the activation of a nearby cryptic branch
point {Padgett et al. 1985; Reed and Maniatis, 1985; Ruskin et

al. 1985).

It has been found that some alternatively spliced
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introns contained multiple branch points associated with a
single acceptor site (Gattoni et al. 1988; Noble et al. 1988;
Helfman and Ricci, 1989) demonstrated that the utilization of
different branch points plays a crucial role in the alterative
splicing of the SV40 pre-mRNA.

The large-T and small-t mRNAs

result from the use of two alternative 5' splice sites joined
to a single shared 3' splice site.

'!'rans-Acting Factors

The observation that

identical

primary transcripts are processed along alternative splicing
pathways,
clearly

according to cell type or stage of development,
demonstrates

differences

in

the

trans-splicing

environments of these cells (Medford et al. 1984; Bretibart et

al. 1985; Leff et al. 1987; Breitbart and Nadal-Ginard, 1987;
Tsurushita et al.
environments
factors.

is

1988).
likely

Such variability in the splicing
determined

by

specific

splicing

Some RNA and protein factors which are required for

constitutive splicing are present in variant forms.

These

variant forms may increase the possibility for regulation of
alternative splice-site selection.
snRNPs, Ul, U2, US, and U4/U6, have all been shown to be
essential for splicing by a combination of antibody and RNase
H mediated degradation

experiments

(Krainer et

al.

1984;

Kramer et al. 1984; Black et al. 1985; Chabot et al. 1985;
Black and Steitz, 1986; Berget and Robberson,
snRNAs showed heterogeneity.

1986).

Some

For example, about 15% of the

total human Ul RNAs may be composed of variant sequences
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(Lund, 1988).

In addition, in mouse, multiple Ul RNAs have

been detected and appear to be developmentally regulated (Kato
and Harada, 1985; Lund et al. 1985).

Likewise, U4 RNAs are

regulated in a developmental and tissue-specific manner in
chicken and Xenopus
1988).

1987; Krof et al.

(Lund and Dahlberg,

Sequence heterogeneity of U2 RNA has not been detected

but it is thought that posttranscriptional base modification
may be developmentally regulated and lead to heterogeneous U2
snRNPs

(Lund and Dahlberg,

snRNPs

which

are

1987) .

developmentally

Thus,

variant forms of

regulated

and/or

tissue

specific may facilitate differential splice-site selection.
In addition to the above snRNPs, several other protein
factors have to be shown to affect alternative splicing.
cellular

factor

isolated

from

mammalian

cells

One

termed ASF

(alternative splicing factor) or SF2 has been found to affect
the choice of alternative 5'-splice sites
1990; Krainer et al. 1990a).

(Ge and Manley,

In vitro splicing studies with

the early region of simian virus {SV40) involving the large Tand small t-splice choices, and a model pre-mRNA substrate
derived from the human p-globin gene, demonstrated that high
concentrations of ASF / SF2 promote the use of proximal 5 ' splice sites,

whereas low concentrations favor the use of

distal 5'-splice sites.
to

specifically

Recently, hnRNP Al has been reported

counteract the

effect

of

ASF/SF2

splice-site selection (Mayeda and Krainer, 1992).

on

the

The hnRNP

Al is not a general inhibitor of ASF/SF2, since both hnRNP Al
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and ASF/SF2 are essential splicing factors
1990b). However,

when two alternative 5 1

available for splicing,

(Krainer et al.
splice sites are

the ratio of hnRNP Al to ASF I SF2

precisely determines which splice site is used in vitro.

High

concentrations of ASF/SF2 activates proximal 5' splice sites,
whereas high concentrations of hnRNP Al favor distal 5' splice
sites with several model and natural alternatively spliced
pre-mRNAs.
may

The regulation of these antagonistic activities

play

an

important

developmental

control

role
of

in

gene

the

tissue-specific

expression

by

and

alternative

splicing of pre-mRNA.
RNA Secondary Structure

that

one way

in

which

Several authors have suggested

sequences

other

than

the

primary

consensus sequences might influence splicing patterns is to
alter the secondary structure within the precursor RNA and
thereby alter the utilization of a splice site (Solnick, 1985;
Eperon et al. 1988; d'Orval et al. 1991; Libri et al. 1991;
Estes et al. 1992).
affect

splice-site

The potential of secondary structure to
selection was

first

artificially constructed transcripts.

demonstrated

with

When an exon was put

into the loop of a hairpin by inserting long inverted repeats
into

the

adjoining

introns,

in

vitro

splicing

apparatus

generated a novel, "jump"-spliced RNA that had the flanking
exons joined directly together, leaving out the exon in the
loop.

To

alternative

a

lesser
splice

extent,

in

vivo,

the hairpin
in

caused the

transfected

Hela

same
cells
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(Solnick, 1985).

The extent by which the exon within a stem-

loop structure was "skipped" was inversely proportional to the
stability of the stem (Solnick and Lee, 1987; Eperon et al.
1988).

Recently,

secondary structure

in

the

chicken fJ-

tropomyosin pre-mRNA has been shown to play a role in the
regulation

of

the

alternative

splicing

of

this

message

(d'Orval et al. 1991; Libri et al. 1991; Guo et al. 1991).
The chicken {J-tropomyosin pre-mRNA is spliced in a tissuespecif ic manner to yield mRNAs coding for different isoforms
of this protein.

Exons 6A and 6B are spliced in a mutually

exclusive manner; exon 6B was included in skeletal muscle,
whereas exon 6A was pref erred in all other tissues.

The

distal portion of the intron upstream of exon 6B was shown to
form stable double-stranded regions with part of the intron
downstream of exon 6B.

This structure repressed splicing of

exon 6B to 7 in a Hela cell extract.
occurred

on

disruption

of

this

Derepression of splicing
structure

followed when the structure was reformed.

and

repression

Thus,

cellular

factors which either stabilize or melt secondary structure may
regulate alternative splicing.

E.

Functional Effects of Alternative Splicing of Pre-mRNA
The functional effects of alternative splicing of pre-

mRNA

is

a

subject

of

considerable

interest.

Strong

correlations have been made between alternative splicing and
biological function.

These cases highlight the importance of
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alternative splicing as a posttranscriptional regulatory event
which

can

expression.

quantitatively

and

qualitatively

control

gene

Alternative splicing in most cases gives rise to

protein isoforms sharing some identical regions, and varying
in some specific domains, thus allowing for the modulation of
protein function, such as regulation of protein localization,
modification of protein activity,
protein activities.

and production of novel

Alternative splicing is also used to

quantitatively regulate gene expression,

by giving rise to

prematurely truncated open reading frames, or by regulating
mRNA stability or translational efficiency via variability in
the untranslated regions.

As a mechanism to regulate gene

expression

protein

and

generate

diversity,

alternative

splicing has advantages over gene rearrangement and extensive
multigene

families.

It

allows

isoforms

without

permanent

content,

and without changes

for

changes

switches
in

the

in

protein

cell

genetic

in transcriptional activity.

Functional effects of alternative splicing are reviewed below.

1.

Protein Localization
Regulated alternative RNA processing is often used to

specify the localization of proteins.

There are a number of

cases of proteins which are either present within the cell or
are

secreted.

protein

gelsolin

For

example,

exists

cytoplasmic protein.

as

the
both

actin
a

filament-severing

plasma

protein

and

a

The two mature proteins are identical

except for an additional 25 amino acid residues at the its
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amino terminus of the plasma isoform.
expressed

from the

The two isoforms are

same gene by the differential use

alternative promoters and alternative splicing of 5'

of

exons

that code for the extra 25 amino acids of the mature plasma
protein and a 27 amino acid cleavable signal peptide that
directs its initial translocation from the cytosol into the
rough endoplasmic reticulum (Kwiatkowski et al. 1986).
functional

differences

have

been

detected

between

No
the

intracellular and extracellular forms of gelsolin.
Avian epidermal growth factor receptor is another example
of a protein that utilizes alternative splicing to generate
membrane-bound and secreted forms (Flickinger et al. 1992).
Epidermal growth factor receptor is a 170 KDa transmembrane
glycoprotein which is encoded by 12 Kb or 8.6 Kb transcripts.
Recently,

a small transcript

(2. 6 Kb)

was isolated.

This

transcript encodes a soluble, secreted and truncated receptor
molecule that can act as an antagonist to inhibit full-length
receptor function.

Sequence analysis of corresponding cDNA

and genomic DNA revealed that the 2. 6 Kb epidermal growth
factor

receptor

splicing.

transcript

is

produced

by

alternative

The 3' end of this transcript diverged from the

sequence of the extracellular ligand-binding domain of the
full length receptor are a result of the utilization of an
alternative polyadenylation signal between exons 12 and 13 of
the full length receptor transcript.
The gene for immunoglobulin µ

(Igµ)

heavy chain also
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gives rise to membrane-bound and secreted forms by alternative
splicing.

The

Igµ

heavy

chain

lymphocytes as a membrane-bound form.

is

present

in

early

B

Upon B-cell maturation,

following antigen stimulation, levels of the membrane-bound
form progressively decrease while the production of a secreted
pentameric form increases.

This switch is acheived by the

alternative use of 3 1 end exons; the early B-lymphocyte form
codes for the hydrophobic membrane-binding segment {Alt et al.
1980; Early et al. 1980; Rogers et al. 1980).

These examples

show that alterative splicing could regulate the distributions
of a protein between subcellular compartments.

The targeting

of protein to different locations involves the use of leader
sequences that are removed from the mature protein during or
after transportation, or by the use of membrane targeting
sequences

which

are

modified

anchoring substituents.
than

one

cell

by

attachment

of

membrane

The distribution of proteins to more

compartment

could

thus

be

regulated

by

alternative splicing of such targeting sequences.
2.

Modulation of Protein Function

Functionally distinct protein isof orms are often produced
by alternative splicing.

Generation of the protein isoforms

with differing functions due to alternative splicing has been
found for some transcription factors {Lillycrop and Latchman,
1992; Morris et al. 1992), receptors (Mosley et al. 1989;
Baumbach et al. 1989; Takaki et al. 1990; Johnson et al. 1991;
Flickinger et al. 1992), ion channels (Schwarz et al. 1988;
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Timpe et al.

1988)

and enzymes

(Imamura and Tanaka,

1982;

Noguchi et al. 1986; Liang et al. 1991).
The RNA encoding

the

octamer-binding transcriptional

factor Oct-2 is alternatively spliced to yield multiple mRNAs
encoding different isoforms of the protein.

Isoforms Oct 2.4

and 2.5 differ from the other forms, Oct 2.1, 2.2, and 2.3, at
their carboxyl termini.
endogenous
effects

Oct-2,

on

When introduced into cells lacking

various

Oct-2

octamer-containing

Latchman, 1992).

isoforms

have

promoters

different

(Lillycrop

and

The Oct 2.1, 2.2, and 2.3 forms stimulate

all octamer-containing promoters.

However, the Oct 2.4 and

2.5 forms can repress some promoters and stimulate others,
depending on the sequence of the octamer motif and its context
within the promoter.
different

isoforms

Thus alternative splicing can generate
of

the

Oct-2

effects on gene expression.

proteins

with

different

Alternative splicing has also

been observed to affect the transcription factor Pit-1 in a
similar manner (Morris et al. 1992).
Changes in receptor functions can be correlated with
alternative

splicing

of

epidermal

growth

factor

receptor

(Flickinger et al. 1992), fibroblast growth factor receptor
(Johnson et

al.

1990;

Johnson

et

al.

1991),

interleukin

receptors (Mosley et al. 1989; Takaki et al. 1990) and growth
hormone receptor pre-mRNAs (Baumbach et al. 1989).

In these

cases,

soluble,

alternatively

spliced

mRNAs

encode

the

secreted or truncated receptors which often lack transmembrane
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domains or cytoplasmic domains,

but contain extracellular

ligand binding domains and retain ligand binding abilities.
One can speculate that the secreted receptors can act as
reservoirs to regulate levels of extracellular ligands,

or

inhibitors to block ligand-mediated responses by preventing
interaction

of

the

ligands

with

membrane-bound

forms

of

receptors.

For instance, alternatively processed mRNA from

the epidermal growth factor receptor gene encodes a soluble
truncated form of the receptor that can inhibit the function
of the membrane-bound receptor by blocking ligand-dependent
cell transformation (Flickinger et al. 1992).
Alternative splicing can also generate enzyme isoforms
with differing enzymatic activities.
isoforms

are

produced

by

Different glucokinase

tissue-specific

alternative

RNA

splicing in liver and pancreatic islet cells (Liang et al.
1991).

Ll is major glucokinase isoform found in liver, and Bl

in islets.

Ll and Bl differ from each other by 15 amino acids

at the NH2 terminus due to occasional skipping of exon 1.

The

Km values of the Bl and Ll isoforms are similar, but the Vmax

of the Bl isoform is 2. 8 fold higher than that of the Ll
isoform.

In addition,

two minor glucokinase isoforms in

liver and islet cells, L2 and B2, generated from mRNAs lacking
51 nucleotides due to the use of an alternate splice acceptor
site in the exon 4,

lack glucose phosphorylating activity.

These results suggest that the alternative splicing of the
glucokinase pre-mRNA dramatically affect the enzyme activities
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of the gene products.
In a limited number of cases alternative RNA processing
gives

rise

functions.

to

mature

products

with

totally

different

Here the alternatively spliced region encodes the

major active site of the product.

This type of alternative

splicing is used in the generation of a number of peptide
hormones.

The calcitonin gene produces both calcitonin and

calcitonin gene-related peptide (CGRP) by alternative splicing
and poly(A) addition site usage (Amara et al. 1982; Jonas et

al. 1985).
coding

Exons 1-3 contain the 5 1 untranslated and common

regions.

Exon

4

contains

the

calci tonin

coding

sequence and a poly(A) addition site and is used in thyroid.
In brain and other neuronal tissue exon 3 is spliced to exons
5 and 6,

which contain the CGRP coding region and its 3 '

untranslated sequences and poly(A) addition site.
of

these

two

different

mRNAs

produces

two

Translation
prehormones;

proteolytic cleavages release the two different polypeptides,
calcitonin
retention

and

CGRP.

while

CGRP

Calcitonin
may

have

functions

in

neuromodulatory

calcium
activity

(Fontaine et al. 1987).
3.

Effects on RNA Stability and Translatability

Many genes produce transcripts with heterogeneity within
the 5 1 and 3'-UTRs.

The untranslated sequences are known to

be involved in regulating translational efficiency
199la,b)

and

RNA

stability

(Brawerman,

1987).

(Kozak,
Thus,

alternative processing involving untranslated regions provides
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the

potential

for

regulated

expression

of

the

same

gene

product in different cells, or for regulating the expression
of different products arising from alternative splicing of
coding regions.

A specific sequence promoting mRNA decay has

been identified in the 3' noncodinq region.

Shaw and Kamen

(1986) have shown that the colony-stimulating factor-1 (CSF-1)
gene produced two transcripts that were

identical

coding region but differed only in the 3 1 -UTR.
contains a
rapidly

repetitive AUUUA element found

turning

over

mRNAs,

and

One 3 1 -UTR

in a

causes

in the

number of

a

dramatic

destabilizing effect when inserted into the 3 '-UTR of (j-globin
mRNA.
the

This suggests that CSF-1 expression can be regulated at

level of mRNA turnover according to the selection of

different 3 1 untranslated sequences.
The

5 1 -UTR

regulation

of

indicated

that

has

been

shown

translational
changes

in

to

be

involved

efficiency.
the

5'-noncoding

Many

in

reports

sequence

messages can make translation more or less difficult.
suspicion

that

complicated

leader

sequence

can

the

of
The

impair

translation for mRNAs containing alternative 5'-UTRs has been
confirmed for some gene transcripts, such as human complement
protein C2 (Horiuchi et al. 1990), murine tissue inhibitor of
metalloproteinases (Waterhouse et al. 1990) and rat insulinlike growth factor I
Features of

the

(Lowe et al. 1987; Foyt et al. 1991).

5 'UTRs which can

influence

translational

capacity of the message include: 1) length; 2) the presence of
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additional upstream open reading frames; and 3) the presence
of secondary structure.

CHAPTER I I I

METHODS

A. Materials

Enzymes

and

(Gaithersburg,

chemicals

MD),

were

Promega

purchased

(Medison,

WI),

from

BRL

United States

Biochemicals (Cleveland, OH) and Sigma (St. Louis, MO).
32P]dCTP

(specific

(specific

activity

activity

400

3,000

Ci/mmole)

(specific activity 1,000 Ci/mmole)
Biochemicals

(Costa Mesa,

Schleicher

Schull

&

Ci/mmole),

CA).

(Keene,

NH) •

[a-

[a- 32P]UTP

[ 35 S]L-methionine

and

were purchased from ICN
Nytran filters

were

from

N•-Benzyloxycarbonyl-L-

arginyl-L-argine 7- amido-4-methylcoumarin (Z-Arg-Arg-AMC) was
from BACHEM Bioscience Inc.
Plasmids phCB79-2
gifts from Ors.
Chicago,

S.J.

Chicago,

(Philadelphia, PA).

(Chan et al. 1986) and phCB96-2 were
Chan and D.F . . steiner

IL).

The

plasmid

(University of

phCB79-2

(Figure

2)

harbors the cDNA for a 2.3 Kb form of human cathepsin B mRNA
containing 237 nt 5 1 -untranslated region

(UTR),

the coding

region for preprocathepsin B, and a 798 nt 3 '-UTR, cloned into
the EcoRI site of plasmid pGEM-2 (Promega).

Adjacent to the

cathepsin B cDNA is an SP6 promoter to drive mRNA synthesis
42
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A

phCB79-2

SP6

T7

,

EcoRI Eco47111 Apal Hindlll

I

'
EcoRI

EcoRI

IE~~~~~1 ~~-'~1~~~~I

5'UTR

pre

pro

Cathepsin B

3' UTR

B
phCB96-2

SP6

,,

,
,,

T7

,

'

EcoRI Eco47111 Apal Hindlll

I

''
''
'
EcoRI

I E....__.~~~_._I-~1
5'UTR

pre

pro

Cathepsin B

Figure 2: Human cathepsin B cDNAs in plasmids phCB79-2 and
phCB96-2.
The 5' and 3' UTRs, and coding region for the
prepeptide, activation propeptide and mature enzyme in the
cathepsin B cDNAs are indicated. Also shown are restriction
sites.
Panel A shows plasmid phCB79-2 and its cathepsin B
cDNA insert. Panel B shows plasmid phCB96-2 and its cathepsin
B cDNA insert. The cDNA insert in phCB96-2 is missing an 88
nt segment (exon 2) present in phCB79-2.

44
and a T7 promoter to drive antisense or cRNA synthesis.

A

single internal EcoRI site interrupts the codon for glycine
328

near

the

carboxyl-terminus

of

cathepsin

B.

Plasmid

phCB96-2 (Figure 2) contains a human cathepsin B cDNA which is
missing an internal 88 nt segment (exon 2) in the 5'-UTR of
phCB79-2, and is bounded at its 3'-end by the same internal
EcoRI site of phCB79-2 which interrupts the glycine 328 codon.
This

cDNA fragment

plasmid pGEM-4Z.
and

T7

is cloned into the EcoRI

site of the

Positioned at each end of the insert are SP6

promoters

to

drive

mRNA

and

cRNA

synthesis

respectively.

B. Solutions
LB Broth:

10 g peptone (Giboco BRL), 5 g yeast extract

(Gibco BRL), 6 g NaCl per liter
SSPE:

10 mM NaH2P04, 0.15 M NaCl, 1.0 mM EDTA, pH 7.4

TBE:

89 mM Tris-borate, 89 mM boric acid, 2 mM EDTA

ssc:

15 mM sodium citrate, 0.15 M NaCl, pH 7.0

TE:

10 mM Tris-HCl, 1 mM EDTA, pH 7.6

DEPC-Trea ted

H.zO:

water

was

treated

with

0.1%

diethylpyrocarbobate for at least 12 hours and autoclaved.
Pl Buffer:

100 µg/mi RNase A (Sigma), 50 mM Tris-HCl, 10

mM EDTA, pH 8.0

sos

P2 Buffer:

200 mN NaOH, 1%

P3 Buffer:

2.55 M KAc, pH 4.8

QBT Buffer:

750 mM NaCl, 50 mM MOPS, 15% ethanol, 0.15%
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Triton X-100, pH 7.0

c.

QC Buffer:

1.0 M NaCl, 50 mM MOPS, 15% ethanol, pH 7.0

QP Buffer:

1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 8.2

Cell Culture

Tumor cells used in these studies included a cultured
human colon carcinoma (from L.C. Erickson, Loyola University
of Chicago, stritch School of Medicine), human melanomas A375P
and A375M (from I.J. Fidler, Anderson Hosp. and Tumor Inst.),
and

human

prostate

Kozlowski,

carcinomas

PC3P

and

PC3M

Dept. of Urology, Northwestern Med.

(from

Sch.).

J.
The

variant A375M and PC3M were derived from the parental lines
A375 (A375P) and PC3

(PC3P) respectively by culturing cells

derived from experimentally produced metastatic lung tumor
nodules.

The variants A375M and PC3M were more metastatic

than the parent

cells

after

metastasis)

after

s.c.

and

i. v.

injection

transplantation

(experimental
(spontaneous

metastasis) into young nude mice (Kozlowski et al. 1984).

The

melanomas A375P and A375M were cultured in Minimum Essential
Medium supplemented with Earle's salts, essential amino acids,
vitamins,

sodium

pyruvate

(110

mg/L),

penicillin

(100

units/ml), streptomycin (100 µg/ml), sodium bicarbonate (2.2
g/L), and fetal bovine serum {10%).

The prostate carcinomas

PC3P and PC3M, and colon carcinoma were cultured in RPM! 1640
supplemented with penicillin (100 units/ml), streptomycin (100
µg/ml) and fetal bovine serum (10%).

70-80% confluent cells
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were subcultured by scraping into 10 ml of serum free media,
pelleting at 500xg and resuspending in fresh media containing
10% fetal bovine serum.

The media were changed three times

weekly.

D. Human Tissues

Normal human kidney,

spleen,

liver,

colon and breast

tissues, and samples of several solid tumors were provided by
the Cooperative Human Tissue Network and the National Disease
Research Interchange.

The tissues were reported to have been

snap frozen at the time of collection and stored at -70°C.
Pathological reports were provided for each tumor specimen.

E. Total RNA Isolation

Total RNAs were prepared from normal human tissues and
solid tumors, and from cultured cells with a method described
by Chomczynski and Sacchi (1987).
tissue was

crushed

in

Briefly, the cell pellet or

liquid nitrogen and homogenized in

denaturing solution containing 4M guanidinium thiocyanate, 25
mM

sodium citrate,

pH

7.0,

0.5%

sarcosyl,

and

0.1

M 2-

mercaptoethanol.

Sequentially,

0.1 volume of 2.0 M sodium

acetate,

1

phenol,

pH

4.0,

volume

of

and

0.2

volume

of

chloroform-isoamyl alcohol mixture (49:1) were added to the
homogenate.

The aqueous phase was collected by centrifugation

and the RNA in the aqueous phase was precipitated with an
equal volume of isopropanol and washed with 70% ethanol.

The
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RNA was redissolved in diethyl pyrocarbonate (DEPC)-treated
water and its integrity was examined by electrophoresis in an
agarose gel (Fourney et al. 1988).

F. Quantification of Catbepsin B mRNA
The RNA dot blot procedure was used to quantify cathepsin
B mRNA.

Total RNA from normal human tissues and tumor cells

were dissolved in a denaturing solution (50% formamide and lOx
SSC) and heated at 65°C for 15 min.

Varying amounts (0.1 µg

to 10 µg) of denatured RNA were spotted onto Nytran filters.
For a cDNA probe phCB79-2 was digested with EcoRI, and was
fractionated by electrophoresis in 0.7% agarose gel.

The DNA

fragment containing human cathepsin B sequence was eluted from
the gel slice by centrifugation through a 1. 5 ml polypropylene
tube which had a hole at bottom and a small amount of glass
wool as a cushion.

The collected DNA was then extracted with

1 volume of phenol/chloroform and precipitated by ethanol.
The

DNA

pellet

was

redissolved

in

the

TE

buffer.

The

approximate concentration of the purified DNA fragment was
determined by agarose gel electrophoresis and comparison to
known amounts of DNA standards.
labeled with

32

The purified fragment was

P-dCTP by the random primer labeling method

according the Protocols and Applications Guide provided by
Promega.

Twenty ng of the DNA fragment in 30 µl of water was

heated at 100°c for 3 min,
After addition of 10 µl

and chilled on ice for 5 min.

of 5X labeling buffer,

2 µl

of a
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mixture of the unlabeled dNTPs (500 mM each of dATP, dTTP,
dGTP), 2µ1 of acetylated BSA (10 mg/ml), 5 µ.l of (a- 32P]dCTP
(3, 000 Ci/mmole,

10 mCi/ml)

and 5 units of Klenow enzyme

(Promega), the mixture was incubated at room temperature for
1 hour.

The reaction was then terminated by heating at 100°C

for 3 min and chilling on ice for 5 min.

After addition of 2

µl of 0.5 M disodium ethylenediamine tetraacetate (EDTA) and
48 µl of water, the labeled DNA fragment was separated from
unincorporated

(a- 32P]dCTP by a

Shephadex G-50

chromatography (Maniatis et al. 1987).

spun-column

The purified labeled

probe was used in hybridization.
The Nytran filter was prehybridized for 4 hours in a
solution containing 50%
(Maniatis et al. 1987),

formamide,

5X Denhardt' s

solution

0.25 mg/ml of denatured salmon sperm

sos,

1.0 M NaCl, 10 mM Na 2HP04 and 0.1% tetrasodium

pyrophosphate.

Hybridization was done at 42°C overnight in a

DNA, 1.0%

fresh mixture of the same solution to which
cathepsin B cDNA was added.

32

P-labeled human

After hybridization, the filter

was washed three times (30 min each time) in 0.2x SSC and 0.5%
SOS at 65°C, and exposed to Kodak XAR film.

To rehybridize

the blot, the cathepsin B probe was removed by washing the
filter three times in O.OlX SSPE and 0.5%
min.

sos

at 95°C for 30

For the internal standard control, the stripped filter

was similarly hybridized with
the chicken 18s rRNA.

32

P-labeled cDNA corresponding to
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G. Northern Blot Analysis
Total
formaldehyde
agarose/0.02%

RNAs
and

were

denatured

subjected

to

formaldehyde

with

formamide

electrophoresis
gel

in

in

a

and
1.1%

3-[N-morpholino]

propanesulfonic acid (MOPS) buffer (0.02 M MOPS, 5.0 mM sodium
acetate, 1.0 mM EDTA, pH 7.0) (Fourney et al. 1988).
were

transferred

to

Nytran

filter,

and

the

The RNAs

filter

was

hybridized as described above.

H. RNase Protection

Assay

Protection assays were performed using a modification of
a described method (Lowe et al. 1987).

The RNase protection

assay, outlined in Figure 3, depends on the production of a
complementary RNA probe of high specific radioactivity which
hybridizes to homologous sequences in mRNA.

The resulting

regions of double strand RNA are resistant to digestion by
RNase T1 and RNase A.

Single stranded regions in the labeled

RNA probe which do not complement the message are degraded.
Labeled RNA fragments
which correspond to
sample.

of characteristic size are produced

specific mRNA species

present

in the

These labeled fragments can be analyzed for size by

electrophoresis in a denaturing gel.
For

construction of the riboprobe vector,

a

445-bp

EcoRI/HindIII cDNA insert, containing sequence corresponding
to the entire 5 1 -untranslated region of the human cathepsin B
mRNA (Figure 4), was isolated from phCB79-2, and ligated into
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SP6
\
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P-UTP

t

T7 RNA polymerase
Riboprobe

~total RNA

__o__
22 22221

~ RNaseA/ RNase T1

ez222221

'777 7771

sequencing gel

Figure 3. Scheme for RNase protection assay. A DNA fragment
containing 5'-end of human cathepsin B cDNA was cloned into
pGEM-2.
A radioactive antisense RNA probe was synthesized
using T7 RNA polymerase and [a- 32P]UTP as described in methods.
The resulting antisense RNA was purified and then incubated
with total RNA for annealing. RNase A and RNase Tl was added
to digest single strand RNA.
The protected double stranded
fragments were analyzed by electrophoresis on a denaturing
gel.
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Figure 4:
The riboprobe for RNase protection assay.
The organization of a human
cathepsin B mRNA, and the sizes of first six exons are shown. A 445 nt antisense RNA
(riboprobe), complementary to the sequence from exon 1 to the middle of exon 5 of the
cathepsin B mRNA, was synthesized for the RNase protection assay outlined in
Figure 3.
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a pGEM-2 vector {Promega) previously cut with EcoRI/HindIII.
After linearizing the plasmid with EcoRI, the human cathepsin
B

riboprobe

was

synthesized

in

20

µl

reaction

mixture

containing 1.5 µg DNA template, 40 mM Tris-HCl {pH 7.5), 6 mM
MgC1 2 , 10 mM NaCl, 2 mM spermidine, 10 mM dithiothreitol, 40
units RNasin, 50 mM each of CTP, ATP and GTP, 20 µM UTP, 5 µM
32

P-UTP (50 µCi, 400 Ci/mmole), and 20 units T7 RNA polymerase

according the Protocols and Application Guide provided by
Promega.

The mixture was then incubated at room temperature

for 2 hours.
1

µl

After transcription, 1 µg of DNase I

of 200 mM vanadyl-ribonucleoside complex

(BRL) and
(BRL)

added, and the mixture was incubated for 15 min at 37°C.

were
The

mixture was then extracted with O. 5 vol of phenol and 1 vol of
chloroform and subjected to purification by a polyacrylamide
gel electrophoresis.

After running the 8% polyacrylamide/8 M

urea denaturing gel,

the 445-base riboprobe was located by

autoradiography and eluted from a gel slice in 400 µl buffer
(2 M ammonium acetate, 1% SOS and 25 µg/ml tRNA).

The labeled

riboprobe was precipitated with 2 volume of 100% ethanol,
dried in vacuum and resuspended in DEPC treated water.
The RNAs

used in the assays were precipitated from 0.5

M NaCl with 2 volume of ethanol, recovered by centrifugation,
and dried in vacuum.

20 µg of total RNA was resuspended in

29.5 µl of hybridization buffer (20 mM Tris-HCl, pH 7.6, 1 mM
EDTA, 0.4 M NaCl, 0.1%
which O. 5 µl

of H20

sos,

and 75% deionized formamide) to

containing 500, 000-700, 000 cpm of the
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labeled riboprobe was added.

The mixture was heated to 85°C

for 5 min and incubated at 45°C for about 16 hr.

After

hybridization, 270 µl of RNase digestion buffer (10 mM TrisHCl, pH 7.6, 5 mM EDTA, 300 mM NaCl, 40 µg of RNase A per ml
(Sigma), and 2 µg of RNase Tl per ml (BRL)) was added, and the
mixture was incubated for 1 hr at 30°C.

SDS was then added to

a final concentration of 0.6% followed by addition 50 µg of
proteinase K.

The mixture was incubated at 37°C for 15 min,

and then extracted with 0.5 volume of phenol and 1 volume of
chloroform.

Twenty µg of tRNA and 2 volume of ethanol were

added to the aqueous layer.

After 30 min at -20°c,

precipitate

was

collected

by

centrifugation,

resuspended

in

formamide

sample

buffer

formamide and o. 2% of bromophenol blue) .

(80%

dried,

the
and

deionized

The sample was

heated to 95°C for 3 min, chilled on ice, and applied to an 8%
polyacrylamide/8 Murea denaturing gel.

After electrophoresis

at 50°C in 0.5x TBE, the gel was dried and exposed to Kodak
XAR film at -70°C overnight.

RNA bands, corresponding to the

alternative 5 '-UTRs were quantitated by densitometry,

and

their sizes estimated by comparing their mobilities with those
of DNA markers.

I. Polymerase Chain Reaction (PCR) Amplification of cDNA
The

first

strand

cDNA

was

synthesized

with

the

Superscript™ RNase H- Reverse Transcriptase (BRL) from total
RNA using random primers according the method described by
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Kawasaki (1991).

The reaction mixture contained 1 µg total

RNA, 100 pmole of random primer mixture (Pharmacia, Alameda,
CA),

40 units RNasin,

dGTP,

and

200

units

1.0 mM each of dCTP,
of

Superscript™

Transcriptase in a final volume 20 µl.

dATP,

RNase

dCTP and

H"

Reverse

Then the mixture was

incubated at room temperature for 10 min and at 42°C for 1
hour.

Four µl of this reaction mixture was used directly as

template for PCR.
cDNA,

PCR

was

oligonucleotide

To amplify the 5 1 region of cathepsin B
performed
primers

with

having

a
the

pair

of

HindIII

specific
and

EcoRI

restriction sites at their termini to facilitate subcloning;
the primers were 5 1 GGGGATCCAACCGCTCCGCTGCGCGC (sense) in exon
1,

and 5 1 GGGAATTCGGTGTGGATGCAGATCCG

(Figure 5).

(anti sense)

in exon

5

The resulting fragment was subcloned into the

HindIII/EcoRI site of the pBluescrip vector (Stratagene, La
Jolla, CA) to give phCBel.4.
cDNA

missing

exons

2

For amplifying the cathepsin B
and

3,

the

sense

primer,

5'CAGCGCTGGGCCGGGCAC, was complementary to 9 nucleotides on
each side of the exon 1-exon 4 junction, and the antisense
primer

was

5 'CCAGGACTGGCACGACAGGC

and

complementary

to

a

sequence present in the flanking 3' untranslated region of all
known, full length cathepsin B mRNAs (Figure 6).

The reaction

mixture contained 4 µl of the template solution (see above),
2.5 units of Tag polymerase (United States Biochemicals), 400
nM of each primer, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM
MgC1 2 , 0.1 mg/ml gelatin, 0.01% Tween 20 and 0.01% NP-40 in a
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Figure 5. Scheme for PCR amplification of 5' -end of cathepsin
B cDNA. Alternatively spliced forms of human cathepsin B mRNA
are shown. The 5' (sense) and 3' (antisense) primers used in
PCR were complementary to the indicated regions in exons 1 and
5 respectively. PCR products of 549 bp, 461 bp and 306 bp are
expected after amplification of the cDNAs containing the full
length 5' UTR, those missing exon 2, and those missing exons
2 and 3, respectively.
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Figure 6.
Scheme for the PCR amplification of cathepsin B
cDNA missing exons 2 and 3.
Three cathepsin B transcripts
which result from alternative splicing in their S' regions are
shown. The cDNA for the transcript lacking exon 2 and 3 was
amplified with a sense primer which is complementary to the
sequence of the exon 1-exon 4 junction, and an antisense
primer which is complementary to the sequence in the exon 11
(3'-untranslated region). A 934 bp PCR product is expected.

57
final volume 100 µl.

Cycling was performed in a Eppendorf DNA

thermal cycler with a profile of 30 sec at 95°C, 1 min at
65°C, and 2 min at 72°C for 30 cycles.

Ten µl of the reaction

product

gel

were

analyzed

by

agarose

electrophoresis,

transferred onto a Nytran filter, and the filter hybridized
with

J.

32

P-labeled human cathepsin B cDNA.

sequencing of PCR Fragments

PCR

reaction

products

were

isolated,

digested

with

HindIII and EcoRI and subcloned into the pBluescript vector
for single strand sequencing by the dideoxy chain termination
method (Sanger et al. 1977).
The

single

described

strand

by Russel

containing

phCBel.4

et

DNA was

al

prepared with the

(1986).

plasmid were

The

method

HBlOl[F+]

patched

onto

LB

cells
plates

containing 100 µg ampicillin/ml and incubated overnight at
37°C.

A portion of each patch was used to inoculate 1.5 ml

modified LB broth (16 g tryptone, 10 g yeast extract, 5 g NaCl
per liter) plus glucose (0.1%) and 100 µg ampicillin/ml in a
culture tube, giving visible turbidity to the solution.
5x10 9-10 10 of helper phage R408

(Promega)

were added.

Next
The

cultures were incubated at 37°C with vigorous agitation for 45 h.

After centrifuging the infected culture, the 1.3 ml of

the supernatant was transferred to a tube containing 0.2 ml of
2. 5 M NaCl

and

20%

polyethyleneglyco-6000

incubated at room temperature for 15 min.

(PEG-6000)

and

The mixture was
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then centrifuged in a microfuge for 5 min at room temperature.
The supernatant was removed by aspiration, and the tube was
briefly recentrifuged to remove the remaining trace of liquid.
The pellet was resuspended in 100 µl of 10 mM Tris-HCl, pH
8.0, containing 2mM EDTA, and extracted with 50 µl of phenol.
The aqueous phase was collected by centrifugation, and the
single strand DNA in the aqueous phase was precipitated with
250 µl of a 25:1 mixture of ethanol and 3 M sodium acetate,
washed with absolute ethanol, dried at 65°C for 10 min and
dissolved in 20 µl of TE solution.
then sequenced with

The single strand DNA was

Sequenase Version

2. o

(United

States

Biochemicals) according the manufacturer's instruction.

K. construction of Expression Vectors
SP6/cathepsin B mRNA expression vectors were made by
inserting
adjacent

cathepsin
to

procedures.

the
The

B

SP6

cDNA

into

promoter,

pGEM2
using

(Promega)
standard

vector
cloning

insert and vector DNAs were prepared by

restriction enzyme digestion (Maniatis et al,

1987).

digestion mixture contained 5 µg of plasmid DNA,

Each

5 µl

of

appropriate restriction lOx buffer, 10-25 units of appropriate
restriction enzyme in final volume of 50 µl.
incubated at 37°C for 1-3 h.

The mixture was

The reaction end point was

verified by electrophoresis of an aliquot of the sample on an
agarose gel.

After restriction enzyme digestion, the vectors

and inserts were separated by agarose gel electrophoresis, and

59
the

DNA

fragments

were

eluted

centrifugation (see above).

from

the

agarose

gel

by

The vector and insert were then

ligated overnight at 14°C with 1 unit of T4 ligase (BRL) in
the assay buffer provided by the manufacturer.
DNA was

transformed

in E.coli

The ligated
Ampicillin

strain HBlOl.

resistant clones were selected,

plasmid was prepared,

and

samples were analyzed by restriction digestion.
The construction of phCB79-2-2 is outlined in Figure 7.
It

contains the shorter 5 1 -UTR lacking exon 2 from phCB96-2,

the entire preprocathepsin B coding sequence, and the shorter
3 '-UTR from plasmid phCB79-2.

Briefly, a 357 bp EcoRI/HindIII

fragment from phCB96-2, containing exons 1, 3, 4 and part of
exon 5, was inserted into EcoRI/HindIII site of pGEM-2 vector
(Promega)

to

make

plasmid

phCBel. 3. 4. 5.

phCB79-2-2

was

constructed by replacing a sequence from NheI site to ApaI
site

of

phCB79-2

phCBel.3.4.5.

with

593

NheI/

bp

ApaI

fragment

from

phCB79-2-2,3 is identical to phCB79-2-2 except

that it is also missing exon 3.

Its preparation is described

A 87 bp Eco47III/ApaI fragment from phCBel.4,

in Figure 8.

containing part of exon 1 and part of exon 4, was used to
replace the corresponding sequence from the Eco47III to the

ApaI site in the phCB96-2 to make phCB96-2-3.
EcoRI/HindIII
inserted

fragment

into

phCBel.4.5.

from phCB96-2-3

the EcoRI/HindIII

site

of

was

A 206 bp

isolated and

pGEM-2,

to

give

Then phCB79-2-2.3 was constructed by replacing

the sequence from the NheI site to the ApaI site of phCB79-2
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EcoRI

phCB96-2

pGEM-2

Eco RI

Nhel EcoRI
Hind Ill

phCBe1 .3.4.5
EcoRI

Eco RI

J<el/Apal

Nhel

Figure 7. Scheme for the construction of plasmid phCB79-2-2.
phCB79-2-2, containing a cathepsin B cDNA lacking exon 2, was
constructed from phCB96-2 and phCB79-2 in two steps. First,
a 357 bp fragment from phCB96-2 was excised with EcoRI and
HindIII, and ligated into the EcoRI/HindIII sites of a pGEM-2
vector to make phCBel. 3. 4. 5.
To make phCB79-2-2 a 593 bp
fragment was removed from phCBel.3.4.5 with NheI and ApaI and
ligated into the corresponding NheI/ApaI site of phCB79-2.
Restriction enzymes used for subcloning in each step are
indicated.
The cathepsin B cDNA fragment in each vector is
shown by double lines.
Also shown are restriction sites in
each vector.
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Figure 8.

Scheme for the construction of plasmid phCB79-2-2. 3

Eco47111

phCBe1 .4

~47111
Hind Ill

Apel

/Apel

EcoRI

pGEM-2

Eco RI

~l/Hindlll
Nhel EcoRI
Eco47111

Hind Ill

phCBe1 .4.5
Eco RI

~/Apel
Nhel

Eco RI
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Figure 8.
Scheme for the construction of plasmid phCB79-22.3. phCB79-2-2.3, containing cathepsin B cDNA lacking exons
2 and 3 was constructed from phCBel.4, phCB96-2 and phCB72-2
in three steps.
First, an 87 bp fragment from phCBel.4 was
removed with Eco47III and Apa!, and ligated into the
Eco47III/ApaI site of phCB96-2 in place of a corresponding
region to make phCB96-2-3.
Second, a 206 bp EcoRI/HindIII
fragment from phCB96-2-3 was ligated into the EcoRI/HindIII
sites of pGEM-2 vector to make phCBel.4.5. Finally, a 442 bp
NheI/ApaI fragment from phCBel.4.5 was used to replace the
corresponding NheI/ApaI segment of phCB79-2 to give phCB79-22. 3. Restriction enzymes used for subcloning in each step are
indicated.
The cathepsin B cDNA fragment in each vector is
shown by double lines. Also shown are restriction sites in
each vector.
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with the 442 bp NheI/ ApaI fragment from phCBel.4.5.

L. In Vitro Transcription and Translation

Plasmids
columns

were

(QIAGEN

manufacturer' s

isolated

Inc.,

by

chromatography

Chatsworth,

instruction.

Two

CA)

on

according

hundred

ml

of

QIAGEN
to

LB

the

broth

containing 100 µg ampicillin/ml was inoculated with E.coli
transformed by the appropriate plasmid, and incubated at 37°C
overnight with vigorous agitation.

The cells were pelleted by

centrifugation, resuspended in 4 ml of Pl buff er to which 4 ml
of P2 buffer was added, and incubated at room temperature for
5 min.

After addition of 4 ml of P3 buffer, the mixture was

centrifuged at 4°C for 30 min (15,000xg). The

supernatant was

then removed and applied onto a QIAGEN-tip 100 column, which
was preequilibrated with 3 ml of QBT buffer.
next washed with 10 ml of QC buffer,
eluted with

5

ml

of

QF

buffer.

The column was

and the plasmid DNA

The

collected

DNA

was

precipitated with 0.7 volume of isopropanol, washed with 70%
ethanol and dissolved in TE buffer.
For in vitro transcription, the isolated plasmid DNA was
linearized

with

XbaI,

and

purified

extraction and ethanol precipitation.

by

phenol-chloroform
Each transcription

reaction contained 5 µg of the appropriate linearized vector,
10 µl sx transcription buffer (Promega), 10 mM dithiothreitol,
50 units RNasin,

0.5 mM each of ATP, CTP, and UTP, 0.05 mM

m7G(5')ppp(5')G and 40 units of SP6 RNA polymerase in final
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volume of 50 µl.

To estimate RNA synthesis, a 3 µl aliquot of

the complete reaction mixture was added to 10 µCi of dried
32P]UTP prior to the start of the reaction.

[~-

After incubation

at 37°C for 1 hour, the transcripts were purified by phenolchloroform extraction and ethanol precipitation, dissolved in
DEPC-treated

water

and

stored

at

-20°c.

After

each

purification step, portions of these samples were analyzed on
a Northern blot to ensure that no loss or degradation of the
RNA had occurred.

Reaction mixtures containing radiolabeled

UTP were treated with 10 µg of tRNA and 5% trichloroacetic
acid, and the insoluble radioactivity measured with a Beckman
LS7500 liquid scintillation spectrometer to determine the
amount of RNA transcribed.
For in vitro translation, 100 ng to 300 ng of capped mRNA
was heated at 65°C for 15 min, added to a reaction mixture
containing 35 µl of rabbit reticulocyte lysate, 40 units of
RNasin ribonuclease inhibitor, an amino acid mixture {minus
methionine) ,

o. 02

mM

each,

and

4

µl

of

[ 3ss )methionine

{l,lOOCi/mmole) at 10 mCi/ml on a final volume of 50 µl.

The

reaction mixture was then incubated at 30°C for various times
from 15 to 60 min.

All samples were kept at 4°C before and

immediately after translation.

M. Analysis of the Translation Products
Five
diluted

µl

to

samples
10

µl

in

from
an

each

translation mixture

electrophoresis

sample

were

buff er
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containing

0.125

mercaptoethanol,

M Tris-HCl

(pH

20% glycerol and

6.8),

2%

SDS,

2%

2-

o. 001% bromphenol blue,

boiled for 3 min, and electrophoresed on a 10% polyacrylamide

sos

gel in an electrode buffer (pH 8.3) which contained 0.025

M Tris, 0.192 M glycine and 0.1% SDS (Laemmli, 1970).
containing the

35

Gels

S-labeled translation products were dried and

autoradiographed overnight at -70°C using an

intensifying

screen and Kodak XAR film (Laskey, 1980).
To measure [ 35 S]methionine incorporation, a 2 µl aliquot
of each translation reaction was incubated in 250 µl of lN
NaOH, 2% H20 2 at 37°C for 10 min.
ice-cold

25%

trichloroacetic

After addition of 1.0 ml of

acid/2%

casamino

samples were incubated on ice for 30 min.

acids,

the

The precipitates

were collected on Whatman GF/A filters by vacuum filtration,
washed with 3 ml of 5% TCA three times and once with 2 ml of
acetone, dried, and the radioactivity measured with a Beckman
LS7500 liquid scintillation spectrometer.

N. Folding of an In Vitro Translation Product
Plasmid
preparation

phCB79-2-2.3
of

was

m7G(5')ppp(5')G

used

as

capped

a

template

synthetic

RNA

for
as

described above. The in vitro translation was described in the
previous section, except that the reaction mixture contained
0.6 µg of synthetic, capped mRNA and a complete mixture of
amino acids (0.02 mM each) in a final volume of 109 µl.
To promote folding of the translation product, the in
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vitro translation mixture {109 µl) was dialyzed against buffer
(0.05

M Tris-HCl,

20%

glycerol,

0.1

mg/ml

bovine

serum

albumin, o. 15 M NaCl, 1 mN di thiothrei tel, and O. 1 mM Na2EDTA)
to which had been added 6.0 M guanidinium hydrochloride.

At

intervals of 10 minutes or 30 minutes the dialysis buffer was
removed, diluted with an equal volume of buffer to reduce the
guanidinium hydrochloride by half, and the dialysis continued
for two additional cycles of dilution.

The final cycle was

followed by dialysis against buffer only (Hager and Burgess,
1980; Vinson et al. 1988) •

The samples were clarified by

centrifugation at 14,000 x g for 15 min, quick frozen, and
store at -20°c for later analysis.
In an alternative procedure, some samples (108 µl) were
treated with 12 µl of a lOX "oxide-shuffling" redox buffer ( lX
contains

O.15 M Tris-HCl,

pH 8. o,

1 mM Na 2 EDTA,

O. 3 mM

glutathione disulfide, and 3. O mM reduced glutathione) and
incubated at room temperature for
Rudolph).

24 hours

(Jaenicke and

Sample were frozen and stored as described above.

These procedures are summarized in Figure 9.

o. Measurement of cathepsin B Activity
Cathepsin B activity was measured using the fluorogenic
substrate N•-Benzyloxycarbonyl-L-arginyl-L-argine 7- amido-4methylcoumarin

(Z-Arg-Arg-AMC)

(Achkar et al.

1990).

The

enzyme was converted to its free thiol form by preincubation
with dithiothretol and EDTA.

A 50 µl sample was incubated
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Capped synthetic mRNA

1

in vitro translation

translated product

dialysis against
decreasing
concentration
Guanidinium-HCI

l
l
l
l
l
l

treatment with
"oxide-shuffling"
buffer

6.0 M GmdCI

addition of 1OX "oxido
shuffling" buffer
(1 X contains 0.3 mM
glutathione disolfide
and 3 mM reduced
glutathione

3.0 M GmdCI

1.5 M GmdCI

0.75 M GmdCI

0 GmdCI

j

incubation at room
temperature for 24 hr

Cathepsin B assay

centrifugation
to remove pellet

Supernatant

Cathepsin B assay

Figure 9.
Procedure for folding of translation products in
vitro. In vitro translated products were treated in one of
two ways to promote proper folding: with an "oxide-shuffling"
buffer to facilitate disulfide bond formation; and with
decreasing concentration of guanidinium hydrochloride with
changes at 10 and 30 min intervals.
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with an equal volume of activation buffer containing 30 mM
dithiothretol and 15 mM EDTA, pH 5.2,

for 30 min at 25°C.

Then 37.5 µ1 of 0.6 M citrate/phosphate buffer, pH 6.2 was
added,

and the reaction was initiated by the addition of 12 . 5

µl of the substrate (1.128 mM in dimethyl sulfoxide (DMSO)) at
a final concentration of 94 µ.M and 8. 3% DMSO.

The AMC product

was quantitated with an SLM/Aminco SPF-500C spectrofluorometer
at excitation and emission wavelengths of 370 and 460 nm,
respectively.

Some samples were also pretreated for 30 min at

37°C with pepsin (0.83 mg/ml) to remove the remainder of the
activation propeptide prior to assay
Rowan et al. 1992).

(Achkar et al.

1990;

CHAPTER :IV

RESULTS

A.

ouantif ication of Total Cathepsin B mRNA in Human Normal
Tissues and Tumors by Slot Blot Analysis

Cathepsin B mRNA in different normal human tissues and
human tumors was quantified by hybridization of RNA slot blots
with labeled human cathepsin B cDNA from phCB79-2
probe.

as the

Total RNAs were isolated from five kinds of normal

human tissues,

skeletal muscle,

kidney,

liver,

spleen and

colon, and from two cultured human melanoma cells, A375P and
A375M

{Chomezynski

and

Sacchi,

1987) .

Agarose

gel

electrophoresis of the total RNAs was performed following
denaturation with formamide and formaldehyde.

The integrity

of the 18S and 28S ribosomal RNA indicated that the isolated
RNAs were largely intact.
Figure lOA shows a representative slot blot result for
cathepsin B mRNA in five normal human tissues and two melanoma
cells.

The specificity of the cDNA probe was verified by a

Northern blot (Figure 11), which shows that the probe only
hybridized to cathepsin B mRNAs.

Cathepsin B mRNA levels in

A375 melanoma variants are higher than those in all the normal
tissues examined.

A375M, which is highly metastatic,·shows a
69
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Figure 10. Slot blot hybridization analysis of human normal
tissues and cultured melanoma cells for levels of cathepsin B
mRNA

RNA
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10

colon
skeletal muscle
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liver
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colon

skeletal muscle
kidney
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liver
A375M
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1

(µg)

0.1
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Figure 10. Slot blot hybridization analysis of human normal
tissues and cultured melanoma cells for levels of cathepsin B
mRNA.
Panel A,
Total RNAs were isolated from normal human
tissues, skeletal muscle, kidney, liver, spleen and colon, and
two cultured human melanoma cells, A375P and A375M. 10 µg, 1
µg or 0.1 µg of total RNA was loaded onto Nytran filter, and
the filer was hybridized with 32P-labeled human cathepsin B
cDNA.
Panel B,
To ensure equal loading of RNA in all the
slots, the blot was stripped and rehybridized to a control
probe, the 32P-labeled cDNA of chicken 18S RNA.
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higher expression of cathepsin B mRNA than A375P which is
poorly metastatic, even after adjustments for differences in
loading.

To ensure that similar amounts of RNAs were present

in each sample, the filter was stripped of the cathepsin B
cDNA probe,
chicken

18S

and was rehybridized to a cDNA probe for the
rRNA

{Figure

lOB).

Intensities

of

the

hybridization signals were measured by densitometry.
Table 1 shows the relative levels of cathepsin B mRNAs in
five normal tissues and two cultured melanoma cells normalized
to the levels of 18S rRNA.

Compared to the spleen, which has

the highest level of cathepsin B mRNA among the five normal
tissues examined, the cathepsin B mRNA levels in A375P and
A375M were 1.5 and 2.3 fold higher respectively.

B.

Quantification of Variant Cathepsin B mRNAs by Northern
Blot and RNase Protection Assay
Cathepsin B mRNAs are heterogeneous due to differences in

processing of 5'- and 3'-ends of the pre-mRNA (Gong et al.
1993).

The variable use of a cryptic 5' splice site in exon

11 with splicing to exon 12 causes the occasional loss of a
polyadenylation signal in exon 11 and results in messages
which differ by about 2 Kb in the lengths of their 3'-UTR.
Variable removal of exon 2 produces messages which differ by
88 nt in their 5'-UTR.

The discovery of multiple cathepsin B

mRNAs generated by the alternative processing of the pre-mRNA
opens up the possibility that it may be a mechanism for
regulating cathepsin B expression in human tissues.
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Table 1. Relative level of cathepsin B mRNA in human tissues
and tumor cells

Normal Tissues
Colon
Breast
Skeletal Muscle
Liver
Spleen
Kidney

Ratio of density
(CB/18s RNA)
0.01
0.21
0.15
0.18
0.30
0.25

Cultured Melanomas
A375P, poorly metastatic
A375M, highly metastatic

0.46
0.68
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To
Northern

investigate
blot

alterative

analysis

was

splicing

performed.

of

the

Figure

3'-UTR,
11

is

a

representative blot which reveals the presence of the 2.3 Kb
and

4. O Kb transcripts

in

normal

human

skeletal muscle,

kidney, liver, spleen and colon, and in the two human melanoma
variants, A375P and A375M.

Densitometric scan of the Northern

blot

that

(Table

2)

revealed

the

ratio

of

the

2. 3

Kb

transcript to the 4.0 Kb transcript only varied by about a
factor 2, from 2.8 to 6.2.

These differences do not appear

large enough to be suggest that variant 3'-UTRs in cathepsin
B mRNA have a regulatory significace.
An RNase protection assay was used to detect and quantify

human cathepsin B mRNAs with differing 5'-ends.

The riboprobe

used is protected by the first 445 bases of mRNA containing
the longer 5'-UTR (Figure 4). Based on the sequences of the
two 5'-UTRs found in human cathepsin B cDNA (Chan et al. 1986;
Gong et al. 1993), hybridization of this riboprobe with human
cathepsin B transcripts

should result

in

three protected

fragments, a 445 nt fragment corresponding to mRNA containing
the

full

length

5'-UTR,

and

276

and

corresponding mRNA lacking exon 2 .

81

nt

fragments

These fragments were

separated on a denaturing gel, and their sizes were estimated
by

comparing

their

mobilities

with

DNA/HaeIII molecular size markers.
seen in Figure 12.

those

of

¢Xl74

RF

These three bands were

The densities of the 276 nt bands were

much higher than those of 445 nt bands in all tumor cells

75

4.0Kb
2.3Kb

Figure 11.
Northern blot of cathepsin B mRNA from human
normal tissues and cultured melanoma cells. Total RNAs were
isolated from normal human tissues, skeletal muscle, kidney,
liver, spleen and colon, and two cultured human melanoma
cells, A375P and A375M. 15 µg of total RNA from each sample
was denatured, electrophoresed on agarose gel and transferred
onto Nytran filter, and the filter was hybridized with llplabeled human cathepsin B cDNA.
The presence of 2.3 Kb and
4.0 Kb transcripts are indicated.
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Table 2.
B mRNAs

Relative proportion of 2.3 Kb and 4.0 Kb cathepsin

Normal Tissues
Skeletal muscle
Kidney
Liver
Spleen
Colon
Cultured Tumors
A375P, poorly metastatic
A375M, highly metastatic

2.3Kb/4.0Kb ratio•
6.2
2.8
6.1

3.5
2.7
5.1
6.0

* The signals of 2.3 Kb and 4.0 Kb bands from Northern blot
were measured by densitometry. Ratios of the signals of these
two bands were calculated.
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examined, including five cultured tumor cells, A375M, A375P,
PC3M, PC3P and colon carcinoma, and three solid tumors, two
colon carcinomas (one a liver metastasis) and a breast cancer.
The densities of these two bands were similar in most of
normal tissues examined,
colon.

such as liver, kidney, breast and

In contrast, in skeletal muscle the density of the 445

nt band was higher than that of the 276 nt band.

The ratio of

the intensity of the 276 nt band to that of the 445 nt band is
a

measurement

of

the

relative

proportions

of

transcripts in human tissues and tumors (Table 3) .

the

two

The ratios

varied from less than 0.1 to 3.2 for normal tissues, and from
6.0 to 20.1 for the tumors.

From the results in Table 3, it

can be seen that the transcripts lacking exon 2 are much more
abundant in human tumors than in normal human tissues.

Figure

12 also reveals the presence of an unexpected fragment of
about 140 nt which was found in significant amount in three
solid tumors and two cultured human melanoma cells, A375M and
A375P.

This fragment arises from transcripts lacking exon 3

(see below).

When the RNase protection assay was performed

with probe alone (without RNA), no protected bands were seen.
When the RNase protection assay was performed without RNase
digestion, only the 445 base fragment was seen (Figure 13).

C.

Amplification of the 5 1 -Ends of Cathepsin B cDNA from
Human Normal Tissues and Tumors by PCR
RNase

protection

studies

revealed

a

fourth

major

protected band (140 +/- 10 bases) with mRNAs from human breast
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Figure 12.
RNase protection of variant 5' -ends of human
cathepsin B mRNAs. After hybridization to total RNA, the 445
nt riboprobe is completely protected from RNase digestion by
transcripts which contain the complete 5'-UTR.
Transcript
lacking exon 2 produce 276 and 81 nt fragments. Panel A, RNA
from normal tissues and two cultured melanoma cell lines.
Panel B, RNA from three different human tumors, two colon
carcinomas (one a liver metastasis) and breast cancer. Panel
C, RNA from cultured human tumor cells. RNA from some human
tumors give rise to a fourth prominent band (*) which _appears
to be about 140 nt in length.
This fragment arises from
transcript missing exons 2 and 3.
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Table 3. Relative proportion of cathepsin B mRNA transcripts
with and without exon 2
Normal Tissues
Colon
Breast
Skeletal muscle
Liver
Spleen
Kidney
Solid Tumors
Colon
Colon (metastasis to liver)
Breast
Cultured Tumors
A375P, poorly metastatic
A375M, highly metastatic
PC3P, poorly metastatic
PC3M, highly metastatic
Colon, unknown

276/445 ratio*
0.8

2.4
< 0.1
2.6
3.2
2.3
20.1

18.6
23.7
6.0
9.6
8.9
12.0

14.4

* The signals of 276 base and 445 nt bands from RNase
protection assays were measured by autoradiography and
densitometry. Ratios of the signal intensities were calculated
after correcting for differences in the (a-32P]UMP content of
each band.
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Figure 13.
Evaluation of the riboprobe used in the RNase
protection assay. RNase protection assay was performed with
probe alone (without RNA), no protected bands were seen.
RNase protection assay was performed without RNase digestion,
only 445 nt fragment was seen (Riboprobe) .

81

and colon carcinomas and human melanomas.

One possibility was

that this fragment originated from a cathepsin B transcript in
which exon 1 was spliced directly to exon 4, deleting exons 2
and 3 (125 base fragment expected in RNase protection assay).
To test this,

the 5 '-ends of the cathepsin B mRNAs

from

skeletal muscle, solid colon carcinoma, cultured tumor cells
A375M

and

PC3M

were

amplified by PCR.

reverse

transcribed

into

cDNA

and

After electrophoresis, the PCR products

were transferred onto a Nytran filter and hybridized with
human cathepsin B cDNA.

This hybridization revealed 549 bp

and 461 bp fragments which were derived from cDNAs which
contain or lack exon 2

(Figure 14) •

The 4 61 bp band was

predominant with RNA from the solid colon carcinoma and the
cultured

tumor

cells,

A375M

and

detectable with RNA from muscle.

PC3PM,

but

was

barely

These results confirmed the

findings obtained with the RNase protection assay.

The 306 bp

band is the expected product for cDNA lacking both exons 2 and
3.

In agreement with RNase protection studies, 306 bp band

was seen with A375M and solid colon carcinoma, but not with
skeletal muscle and PC3M.

D.

Molecular Cloning of Human cathepsin B cDNA Lacking Exons
2 and 3

In order to characterize the transcript lacking exons 2
and 3, a cDNA corresponding to this transcript was cloned by
PCR.

Total

RNA

isolated

from

A375M

cells

was ·reverse

transcribed and the single stranded cDNA was amplified by PCR.
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Figure 14. PCR amplification of the 5'-ends of cathepsin B
cDNA from human normal tissues and tumors. This figure shows
a
Southern blot of products obtained after
reverse
transcription and PCR amplification of the 5'-ends of
cathepsin B cDNA from two human tumor cell lines, A375M
(melanoma) and PC3P (prostate carcinoma) , a solid colon
carcinoma, and normal skeletal muscle.
The pair of primers
used for the PCR were complementary to regions in exon 1 and
exon 5. The 549 and 461 bp bands are from cDNAs which contain
and lack exon 2 respectively.
The 3 06 bp fragment is the
expected product of cDNA which lacks both exons 2 and 3. The
306 bp band was only seen with cDNAs from tissues which
yielded detectable levels of the 140 nt band in RNase
protection studies (Figure 12).
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The primers used in PCR have the HindIII and EcoRI restriction
sites at their termini, and were designed to amplify the 5'end of cathepsin B cDNA from exon 1 to the middle of exon 5 as
described in the Methods.

Because the level of cathepsin B

cDNA missing exons 2 and 3 was low,
separated

by

smaller than

agarose
461

gel

the PCR products were

electrophoresis,

bp were eluted

and

fragments

and reamplified

by PCR.

Figure 15 shows the 306 bp product which has the expected size
of a cathepsin B cDNA fragment containing exon 1, exon 4 and
part of exon 5, and missing exons 2 and 3.

This PCR fragment

was cloned into the pBluescript vector (Stratagene) to make
the

plasmid

phCBel. 4

for

single

strand

sequencing.

The

complete sequencing of several positive clones confirmed that
the 306 bp PCR product was derived from cathepsin B mRNA which
lacked

exons

2

and

3•

Figure

16

shows

a

portion

representative sequence which contains an exon 1 junction.

of

a

exon 4

In order to further characterize the transcript

lacking exons 2 and 3, a fragment from phCBel.4, containing
part of exon 1 and part of exon 4, was cloned into phCB79-2 to
replace the corresponding region containing exons 2 and 3.
The resulting plasmid, phCB79-2-2.3, harbored a cathepsin B
cDNA lacking exons 2 and 3 as described in Methods (Figure 8) .

E.

Detection of Cathepsin B mRNA That Is Missing Exons 2 and
3 by PCR

Total RNA from tumor cells was used to clone a cathepsin
B

5' cDNA fragment which is missing exon 2, noncoding, and
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a b
bp

-615
-492
-369
-246
-123
Figure 15.
PCR amplification of 5'-end of cathepsin B cDNA
missing exons 2 and 3.
5 1 -ends of cathepsin B cDNAs were
amplified from A375M cells as described in Figure 15.
Products smaller than 461 bp were isolated by agarose gel
electrophoresis and used as templates for reamplif ication by
PCR.
A 306 bp fragment (indicated by arrow) was obtained,
which is expected product of cathepsin B cDNA missing exons 2
and 3.

85

3•
T-140

AGCT

c

A
A
A

c

A
C

Exon 4

G
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G

c
c

G-127
G--114
G
T

c

G
C
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Exon 1

A

c

G
T--124
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Figure 16. Sequence of the 306 bp PCR product amplified from
cathepsin B cDNA in A375M cells.
The 306 bp PCR product,
obtained as described in Figure 15, was cloned into EcoRI and
HindIII sites of pBluescript vector, and sequenced.
The
complete sequence of several positive clones revealed that
they arose from cathepsin B transcript which lacked ·exons 2
and 3. A portion of a representative sequence corresponding
to the exon 1 - exon 4 junction is shown.
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exon

3,

encoding

activation

the

signal

propeptide.

prepeptide

Reverse

and

part

transcription

of

the

and

PCR

amplification was next used to confirm that human tumors
contain a corresponding mRNA which contains the remainder of
the procathepsin B coding sequence and the 3'-UTR present in
other

cathepsin

amplification,

B

messages

(Figure

17).

For

the

the 5' primer (sense primer) was complementary

to 9 nucleotides on each side of the exon 1 - exon 4 junction,
and the 3' primer (antisense primer) was complementary to a 20
nucleotide sequence present in the flanking 3' untranslated
region of all known, full length cathepsin B mRNAs {Chan et

al. 1986).

cDNA templates prepared from PC3M cell RNA, and

the plasmids

phCB79-2

and phCB79-2-2. 3,

were

included to

verify the specificity of the sense primer for the exon 1-exon
4 junction.

Previous RNase protection studies were unable to

detect any cathepsin B transcripts in PC3M that were missing
exon 3; plasmid phCB79-2 harbors a full length cathepsin B
cDNA,

including the complete 3 '-UTR of the

2. 3 kb human

cathepsin B mRNA; and plasmid phCB79-2-2.3 is identical to
phCB79-2 except it is missing exons 2 and 3.
product,

obtained

with

phCB79-2-2.3

as

The 934 bp PCR
a

template,

is

indistinguishable in size from the PCR products obtained with
the cDNAs from the two human melanomas variants, A375M and
A375P.

The identity of the PCR products which were amplified

from cathepsin B cDNA was confirmed by hybridization with
human cathepsin B cDNA.
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F.

In Vitro Translation of variant cathepsin B mRNA
RNase protection assays have shown striking differences

in the relative abundances of cathepsin B mRNAs which differ
in their 5 1 -ends in normal human tissues and in human tumors.
Exon 2, which is more frequently absent from the 5'-UTRs of
cathepsin B mRNAs from human tumors, has features which can
affect the translational efficiency of the mRNA.

It extends

the length of the 5 1 -UTR, contains adjacent start and stop
codons upstream of the normal start site, it is GC rich, and
computer analysis indicates the potential for the formation of
secondary structure between a region of exon 2 and a nearby
downstream sequence.

Thus the cathepsin B mRNAs which differ

in their 5 1 -UTRs may vary in their ability to direct protein
synthesis.

A cathepsin B transcript lacking exon 3 has also

been found in melanoma cells,
carcinomas.
and

encodes

and solid colon and breast

Since exon 3 contains the translation start site,
the

signal

prepeptide

and

7

residues

of

propeptide, it was unclear whether such transcripts containing
an exon 1 - exon 4 splice junction would be translationally
active.

However,

there is an in-frame methionine codon,

corresponding to amino acid 52 in preprocathepsin B, which
potentially could be used for translation initiation.

To

determine the translational activities and translatability of
the various human cathepsin B mRNAs which differ in their exon
composition, an in vitro transcription and reticulocyte lysate
translation system was used as described in Methods.
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The

SP6

promoter

in pGEM-2

vector has

been used to

generate specific transcripts with biological activity (Melton

et

al.

1984).

Cathepsin

B

cDNAs

with

different

exon

composition in their 5'-ends were cloned into the EcoRI site,
adjacent to the SP6 promoter as described in Methods.
2,

phCB79-2-2

and phCB79-2-2. 3 were used to generate the

corresponding cathepsin B mRNA species.
phCB79-2

contains

preprocathepsin

phCB79-

the

coding

longer

sequence,

Cathepsin B mRNA from

5'-UTR,
and

the

the
shorter

entire
3 '-UTR.

Cathepsin B mRNA from phCB79-2-2 is the same as that from
phCB79-2 except that it has shorter 5 1 -UTR lacking exon 2.
Cathepsin B mRNA from phCB79-2-2.3 is the same as that from
phCB79-2 except that it contains the shorter 5'-UTR, and is
also missing exon 3 encoding the prepeptide and 25 residues of
the propeptide.

Translation from the next in-frame methionine

codon should produce a protein lacking the signal peptide and
34 of the 62 residue propeptide.

Capped mRNAs transcribed in

vitro were examined by electrophoresis on an agarose gel,
transferred onto a Nytran filer, and the filter was hybridized
with human cathepsin B cDNA.

The autoradiogram in Figure 18

shows that essentially all of the transcripts were full length
and of the expected size.

Phenol/chloroform extraction and

ethanol precipitation did not cause the degradation and loss
of the transcripts.

These transcripts were used for in vitro

translation in the reticulocyte lysate in the presence of
methionine.

35

5-
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Translation activities were determined by varying both
RNA

template

concentration

translation reaction.

and

incubation

time

for

the

The results were expressed both as the

rate of labeled methionine incorporation at constant template
concentration and as the specific activity of the template
(incorporated
methionine

methionine/ng
labeled

RNA)

protein

at
was

constant

time.

precipitated

trichloroacetic acid, and radioactivity measured.

35

S-

with

Figure 19

shows the translational activities of two cathepsin B mRNAs
with or without exon 2 with respect to the amount of RNA and
time of incubation at 30°C.

From this figure it can be seen

that cathepsin mRNA with the shorter 5 1 -UTR, the major isoform
from tumors (phCB79-2-2) is about twice as active as the mRNA
with the longer 5'-UTR, the major isoform from normal tissues
(phCB79-2).

35

S-methionine labeled protein was also analyzed

by sos electrophoresis and autoradiography.

The protein yield

from cathepsin B mRNA with the shorter 5'-UTR (phCB79-2-2) was
higher than that from the mRNA with the longer 5 1 -UTR (phCB792)

(Figure 20).

Figure 20 also shows a single major band of

the size expected (approx 37 kDa) for nonglycosalated form of
preprocathepsin B (339 amino acids)

(Chan et al. 1986).

The

results showed in Panel B were same as those in Panel A,
except varying

amount

of RNA template was

used,

and the

incubation time was 1 hour.
In order to study the translation potential of cathepsin
B mRNA lacking exon 3, the

synthetic RNA missing exon 2 and
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Figure 19.
Rates of in vitro translation
cathepsin B mRNAs containing variant 5 1 -UTR
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Figure 19.
Rates of in vitro translation of synthetic
cathepsin B mRNAs containing variant 5 1 -UTRs.
Panel A, the
specific activities of the two variant templates were
determined by incubating reticulocyte lysates for 60 min with
the indicated concentrations of capped cathepsin B synthetic
RNAs as described in Methods. The amount of [ 35 s] L-methionine
incorporated into trichloroacetic acid-insoluble products was
measured with a liquid scintillation spectrometer. Panel B,
the effect of time on [ 35S]L-methionine incorporation into
trichloroacetic acid-insoluble products was measured as
described for panel A using 300 ng of template in a final
volume of 50 µl.
Closed circles, mRNA template used in the
translation was transcribed from clone phCB79-2-2 lacking exon
2; open circles, from clone phCB79-2 containing exon 2.
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Figure 20.
SOS-PAGE electrophoresis analysis of in vitro
translation products from cathepsin B mRNAs with and without
exon 2.
synthetic capped cathepsin B mRNAs were incubated
with a reticulocyte lysate at J0°C as indicated. Five µl of
the in vitro translation reaction mixture were then
electrophoresed
on a
10% polyacrylamide-SDS
gel
and
autoradiographed. phCB79-2-2, RNA template transcribed from
phCB79-2-2 lacking exon 2; phCB79-2, RNA template from phCB792 containing exon 2; control, no RNA template added to the
translation reaction.
Panel A,
JOO ng of synthetic capped
cathepsin B mRNAs in 50 µl of a reticulocyte lysate were
incubated for the time indicated.
Panel B,
the indicated
amounts of synthetic capped cathepsin B mRNAs in 50 µl of
reticulocyte lysate were incubated for 1 hour.
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3

from

phCB79-2-2.3

was

also

in

translated

vitro

in

reticulocyte lysate, and analyzed by SOS-electrophoresis and
autoradiography.

Figure 21 compares the translation products

of all three cathepsin B transcripts containing variant 5'ends.

Not only can the transcript missing exons 2 and 3

(phCB-2-2.3)

be translated in vitro, it is seen to be much

more active than the other two isoforms.

A densitometric scan

of the autoradiogram in Figure 21 revealed that mRNA obtained
from

phCB79-2-2.3

efficiently

was

than

translated

phCB79-2-2

efficiently than phCB79-2.

and

nearly

4

times

more

nearly

8

times

more

Second, the resulting product is

of the expected size (about 32 KDa) for translation initiation
from the first methionine codon in exon 4 (288 amino acids).

G.

Refolding of a Truncated cathepsin B Produced by the In
vitro Translation of mRNA Lacking Exons 2 and 3

Reticulocyte
message

lacking

lysates
exons

2

appear
and

methionine codon (residue 52).
protein product

is

to

3

be

from

able to
a

translate

second

in-frame

The expected 32,000 dalton

obtained which should

lack the

signal

peptide and first 34 residues of the 62 amino acid propeptide
region.

To determine if this product can be folded to produce

a native structure, it was treated in one of two ways: with an
"oxido-shuffling" buffer containing glutathione disulfide and
reduced glutathione to facilitate disulfide bond formation
(Jaenicke

and

Rudolph,

1989) ;

and

with

decreasing

concentration of guanidinium hydrochloride as described in

98
Methods (Hager and Burgess, 1980; Vinson et al. 1988).

The

ability to acquire enzymatic activity is a highly stringent
test of protein folding

into a

native conformation.

The

results in Figure 22 demonstrate that the missing propeptide
region of the 32,000 dalton protein product is not essential
for correct folding and acquisition of enzymatic activity.

In

vitro translation reactions which lacked the synthetic mRNA
templates

gave

no

activity

under

any

of

the

refolding

conditions tried (data not shown) .
No systematic study was made of the conditions necessary
to

optimize

the

in

translation product.

vitro

folding

of

the

32,000

dalton

Thus, the maximum recovery of activity,

obtained by dialysis against decreasing concentrations of
guanidinium hydrochloride at intervals of 30 minutes, is still
likely to be a lower limit.

Using kinetic constants reported

for Z-Arg-Arg-NMec hydrolysis by rat cathepsin B (Tchoupe et

al. 1991), and the amount of

35

S-methionine incorporated into

TCA precipitable products, we estimate that as much as 2% of
the synthetic truncated protein may have acquired a native
structure.

This level was easily measured by the standard

cathepsin B assay.

Also noteworthy is our finding that the

guanidinium hydrochloride treated product was active

(33%)

prior to treatment with pepsin to remove the remainder of the
activation

propeptide.

Either

the

loss

of

the

entire

activation propeptide is not needed for activation, or some of
the enzyme underwent autolysis during folding which removed
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Figure 22. Refolding of a truncated cathepsin B produced by
the in vitro translation of mRNA missing exon 2 and 3. Capped
synthetic mRNA, prepared with plasmid phCB79-2-2.3 as a
template, was translated by a reticulocyte lysate as described
in Methods.
Refolding was initiated by sequential dialysis
against decreasing concentrations of guanidinium hydrochloride
with buffer changes at 10 or 30 min intervals, or by treatment
with a glutathione disulfide/reduced glutathione "oxidoshuffling" buffer. Enzymatic activity is expressed as fmol of
7-amino-4-methylcoumarin (AMC) released from Z-Arg-Arg-NMec
per min per µg of synthetic mRNA translated. Activity was
measured before and after treatment with pepsin to remove the
remainder of amino-terminal propeptide.
No activity was
observed when synthetic mRNA was withheld from the translation
reaction.
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the

remainder

of

the

propeptide.

The

"oxido-shuffling"

treatment of the in vitro translated product did not yield an
active enzyme species.

CHAPTER V

DISCUSSION

A.

Multiple Forms of Cathepsin B Transcripts in Human Tissues

Cathepsin B cDNA cloned from normal human kidney and the
hepatoma cell line, HepG2, are heterogeneous
1986; Gong et al.

1993) .

(Chan et al.

Northern blotting revealed the

presence of 2.3 and 4.0 Kb transcripts (Figure 11).

Analysis

of the cloned cDNAs from both sources has further identified
four cathepsin B transcript types as shown in Figure 23.

In

this present work, I have also identified a fifth type which
is present in some human tumors, by using a combination of PCR
and RNase protection assays.

Transcript type 1

( 4. O Kb)

contains a 237 nt 5' untranslated region (5'-UTR), 1017 nt
encoding preprocathepsin B, and about a 2800 nt 3'-UTR, while
type 2 is identical to type 1 except for the deletion of an 88
nt segment in the 5 1 -UTR (Figure 23).
4 (2.3 Kb) contain a 789 nt 3'-UTR.
in that type 4 has

Transcript types 3 and
The types 3 and 4 differ

the same 88 nt deletion in the 5'-UTR

found in the type 2 transcript.

The transcript type 5 has the

88 nt deletion which is found in the transcripts type 2 and 4,
and also has an additional 151 nt deletion corresponding to
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Figure 23.
Variant cathepsin B transcripts in human tissues.
Overlapping cDNA
clones corresponding to types 1, 2, 3, and 4 were isolated from human kidney and
HepG2 phage libraries. The type 5 transcript was cloned from human melanoma cells
and characterized by PCR as described in the text. The small open box indicates the
exon 1. The solid box indicates the 88 nt 5' untranslated segment which was deleted
in transcript types 2, 4, and 5. The type 5 transcript also has an additional 151
nt deletion corresponding to the signal peptide (S) and 7 amino acid residues of the
propeptide (P). The hatched box indicates the alternative 3' untranslated region.
The part of the 3 1 untranslated region in the transcript types 1 through 5, which is
common to all full length cathepsin B mRNAs, is also shown. The remainder of the 3'
untranslated region in the type 5 transcript has not been characterized.
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the

signal

peptide

propeptide.

and

25

amino

acid

residues

of

the

The 3'-UTR of the type 5 transcript has not yet

been identified.

The preprocathepsin B coding sequence was

identical in all transcripts except for type 5 which lacked
the

exon encoding signal peptide and

25

residues

of

the

propetide.
Cloning

and

sequencing

the

human

cathepsin

B

gene

demonstrated that the multiple cathepsin B transcripts were
derived from alternative processing of the pre-mRNA (Gong et

al. 1993).

Figure 24 shows the organization of the human

cathepsin B gene.

Phage AhCB107 contained a 11,500 bp insert

which included the first two exons, which corresponded to the
5' untranslated sequences.

Phage AhCB102 contained a 13,500

bp

the

insert

which

included

entire

coding

sequence

preprocathepsin B divided into 9 exons numbered 3-11,

of
and

contained alternative 3 1 -UTRs located in exon 11 and exon 12.
Thus, RNA processing at a cryptic intron donor site located in
exon

11

and

splicing

to

exon

12

deleted

the

first

polyadenylation signal and generated the longer alternative
3'-UTR found in transcript types 1 and 2. In contrast, the 2.3
Kb transcripts

(types

3

and

4)

are

polyadenylation signal in exon 11.

terminated after the
The deleted 88 nt 5'

untranslated sequence found in transcript types 2 and 4 is due
to exon skipping in which exon 1 is spliced directly to exon
3.

The 239 nucleotide deletion from the 5 1 end of transcript

type 5 is also due to exon skipping in which exon 1 is spliced
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Figure 24. Organization of human cathepsin B gene. The introns and exons are shown.
The solid areas are the regions which encode preprocathepsin B.
Phage AhCB107
contains a 11, 500 bp insert which include first two exons containing the 5'
untranslated region. Phage AhCB102 contains a noncontiguous 13,500 bp insert which
includes the remaining 9 exons numbered 3-11. Also shown are restriction sites.
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directly to exon 4.
The nucleotide sequences of the cathepsin B gene at all
the exon -

intron junctions conform to the canonical GT/AG

rule (Table 4)

(Breathnach and Chambon,

1981), so that the

generation of cathepsin B transcripts with variant 5 '-ends can
not be explained simply as the result of a poor splice donoracceptor pair between exons 1 and 2, and between exons 2 and
3.

Similarly,

the

generation of cathepsin B mRNAs with

variant 3'-UTRs can not be explained as being due to a poor
splice donor-acceptor pair between exons 11 and 12.

Factors

which regulate alternative splice selection will be described
later.
In

addition

transcripts
reported.

in

to

Figure

these
23,

five
other

types

of

transcripts

cathepsin
have

B

been

Human colorectal tumors contain low levels of two

additional messages of 1.5 Kb and 3 Kb (Murnane et al. 1991).
Human osteoclastomas, which also consist of large numbers of
apparently normal osteoclasts, contain 2.4,

1.9 and 1.2 Kb

cathepsin B-related mRNAs (Page et al. 1992) .

The origins and

sequences of these transcripts are unclear.

In my studies,

transcripts smaller than 2.3 Kb were not detected by Northern
blot analysis.
Multiple forms of cathepsin B transcripts have also been
found in murine melanomas

(Qian et al.

1989).

Murine B16

melanoma cells contain three transcripts for cathepsin B, a
2. 2 Kb form

also

seen in normal tissues,

and two

larger
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Table 4.
gene

exon

Exon-intron organization of the human cathepsin B

exon
size

5'splice
donor

intr on
size

3'splice
acceptor

CGCTGGgtgag •..

3500 bp

UT
••. tcccagGCTGGT
5

5' UT

1

124 bp

1

2

88

UT
CGAGTAgtaag .•.

5000

5' UT
... ctccagGTGGAT

3

151

TrpGln
TGGCAGgtagg .••

820

AlaGly
•.• ttccagGCCGGG

4

86

GlnArg
CCAGAGgtgag ••.

1450

ValMet
... atccagAGTTATG

5

115

CysTrp
TGCTGGgtaag .••

1750

AlaPhe
... ctgcagGCCTTC

6

119

AspGly
GGACGGgtaag ..•

750

CysAsn
... tttcagCTGTAAT

7

86

HisVal
CATGTAGgtaag ...

230

GlyCys
•.. catcagGGTGCA

8

114

HisTyr
CACTACGgtaag ...

470

GlyTyr
... ttccagGATACA

9

117

Lysser
AAGTCAGgtgct ...

1380

GlyVal
••• tttcagGAGTGT

10

129

AspAsn
GACAATGgtgag ...

470

GlyPhe
. .. tcccagGCTTCT

11

142•

ATCGGGgtaga ...

823

. .. ctgcagAGAATC

5

1

3' UT

3' UT

12

2700

*Exon 11 = 886 bp for 2.3 Kb cathepsin B mRNAs (types 3 and 4)
in which the alternative splice site donor site is not
utilized. UT stands for untranslated.
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transcripts of 4 Kb and 5 Kb only observed in the melanomas.
Recently, a 4 Kb message for cathepsin B has been reported in
metastatic ras-transf ormed NIH 3T3

cells

(Chambers et al.

Moin et al (1989), employing a human cathepsin B cDNA

1992).

probe, have also observed a 4 Kb transcript in normal mouse
liver.

However,

Qian et al

(1989;

199lc)

were unable to

detect 4 and 5 Kb messages for cathepsin B in normal mouse
liver,

kidney,

and spleen using either a cathepsin B cDNA

probe or a fragment from the 3 1 -end of the mouse cathepsin B
gene specific for the larger transcripts from melanoma cells.
These

variant

transcripts were

found

to

encode

the

same

cathepsin B percursor protein but to differ in the lengths of
their 3'-untranslated regions (Qian et al. 1991b; Qian et al.
1991c).

The use of alternative polyadenalation signals, which

is also seen with the human cathepsin B gene, explains the
differences between these variant cathepsin B transcripts in
mouse melanomas.

B.

Levels of Expression of variant cathepsin B mRNAs in Human
Normal Tissues and Tumors
Many

reports

have

cathepsin B and cancer.
been

correlated

with

indicated

an

association

between

Elevated levels of cathepsin B have
increased

metastatic

potential

or

invasiveness in a variety of tumors from humans (Pietras and
Roberts,

1981;

Recklies

et

al.

1982;

Dufek et al.

1984;

Watanabe et al. 1989; Sheahan et al. 1989} and rodents, (Sloane
et al. 1982; Koppel et al. 1984; Sloane et al. 1986).

Indeed,
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elevated cathepsin B expression has been thought to be a
marker of the tumorigenic and/or malignant state (Sloane et
al. 1982; Koppel et al. 1984).

Most of these studies used

enzymatic or immunochemical methods to detect and quantitate
the enzyme.
enzyme

However, using activity measurements to estimate

levels

suffers

from

uncertainties

concerning

the

specificity of the substrates, and the presence of different
amounts of endogenous inhibitors and activators in different
tissues which may lead to an under- or over-estimation of the
enzyme.

Immunochemical methods may be compromised by the

cross-reactivity between closely related cysteine proteinases
(Wiederander and Kirschke, 1986).

In this present study, I

have employed cDNA for human cathepsin B to examine

its

expression in normal human tissues and cultured melanoma cells
of different metastatic properties.
melanomas

A375P

(metastatic)

(parental,

studied.

metastatic)

and

for

A375M

are 1.5 and 2.3 fold higher respectively than

that for kidney and spleen,
expression

poorly

The mRNA levels

of

the tissues with the highest

cathepsin B among

the

five

normal

tissues

This result is in agreement with the reports of

enhanced cathepsin B activities observed in a

variety of

tumors such as murine fibrosarcomas (Keren and LeGrue, 1988),
human

liver

carcinoma
(Pietras

cancer

(Dufek

(Mort et al.
and

Roberts,

(Recklies et al. 1982).

et

1981),
1981)

al.

1984),

human

ovarian

human genital tract cancer
and

human

breast

carcinoma

The elevated levels of cathepsin B
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mRNA in human melanoma cells suggested that in these cells
cathepsin B expression is regulated, at least in part, at the
level of transcription and/or mRNA stability.
Post-transcriptional mechanisms may also be involved in
the regulation of cathepsin B expression.

As mentioned above,

cathepsin

to

B mRNA

is

heterogeneous

processing of the 5'- and 3'-ends.
5'

splice donor sites

differ

in

the

lengths

due

differences

in

The selection of variant

in exon 11 produces messages which
of

their

3 '-UTRs.

Although

the

functional significance of mRNAs which vary in their 3'-UTRs
is not known in most cases, modification at the 3'-ends of
messages have been shown to affect rates of mRNA turnover
(Brawerman,

1987; Ross,

1988) and ability to be translated

into protein (Kruys et al. 1987).

We have shown that both 4. O

Kb (types 1 and 2 in Figure 23) and 2.3 Kb transcripts (types
3 and 4 in Figure 23) were expressed in the normal tissues we
examined and in cultured melanoma cells.

There may be subtle

differences in the expression of the 2.3 Kb transcript versus
4. o Kb transcript in certain tissues

(Table 2) .

As large

differences in the relative abundances of the 2.3 and 4.0 Kb
transcripts were not observed between normal tissues and tumor
cells, the regulatory significance of these two cathepsin B
mRNA forms is unclear at present.

The significance of the

longer 3 1 -UTRs in the 4.0 kb and 5.0 kb cathepsin B mRNAs in
murine tumors also remains unknown.
Human cathepsin B transcript types 2 and 4 (Figure 23)
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were found to result from the occasional skipping of exon 2
during pre-mRNA processing, resulting in an 88 nt deletion
from their 5'-UTRs.

Differences in the length of the 5'-UTR

of the messages has also been shown to affect mRNA stability
(Brawerman,

and translation efficiency (Young et al.

1987)

1981; Waterhouse et al. 1990; Horiuchi et al. 1990; Manzella
and Blackshear, 1990; Foyt et al. 1991; Bares et al. 1991; Kim

et al. 1992).

In this study, I have observed a greater than

30 fold difference in the relative levels of the two types of
messages in normal human tissues (Table 3).
B

mRNAs

which

contain

the

truncated

Thus, cathepsin

5'-UTR

were

barely

detectable in skeletal muscle, but were the majority in liver
and spleen.

Human tumors not only contained higher levels of

mRNA for cathepsin B, but the preponderant messages in tumors
also

contained

the

shorter

5'-UTR

(Table

3).

These

observations suggest that alternative processing of the 5'-UTR
of cathepsin B pre-messages may contribute to the regulation
of cathepsin B expression.
mRNA

with

variant

5'-UTR

The differential expression of
in

different

tissues

has

been

demonstrated for some other genes, for example, human insulinlike

growth

factor

II

gene

(Shen

et

al.

1988),

human

complement protein C2 (Horiuchi et al. 1990), mouse complement
factor B gene (Nonaka et al. 1989), mouse a-amylase gene (Shaw

et

al.

1985)

and

Drosophila

alcohol

dehydrogenase

gene

(Benyajati et al. 1983; Bond and Davidson, 1986).
Another potentially significant finding in this study is
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the presence in human breast and colon carcinomas and in human
melanoma of a fifth type of cathepsin B message which lacks
exon 2 (non coding) and also exon 3 (encoding the 17 residue
signal peptide and 25 residues of the activation propeptide)
(Figure 12 and 15).

The 5'-end of this transcript was cloned

by PCR techniques (Figure 15) and its identity was confirmed
by sequencing

(Figure 16).

Reverse transcription and PCR

amplification confirmed that this transcript contained the
remainder of the procathepsin B coding sequence and the 3'-UTR
characteristic of normal cathepsin B transcript (Figure 17).
Further characteristic of this transcript and its significance
in the regulation of cathepsin B expression are discussed
below.

c.

Mechanisms of Alternative Splicing
The mechanisms involved in the regulation of alternative

splicing are
presently

the

well

subject of

understood,

intense study.

several

themes

Though not
are

emerging.

Alternative splicing often appears to be acheived by subtle
variations of the basic mechanisms of RNA processing.

Many

studies have shown that differential splice site utilization
involves the selection of a variant of a cis element, such as
the consensus sequence around the 5' and 3' splice-site and
around the branch point (Ruskin et al. 1985; Aebi et al. 1986;
Smith and Nadal-Ginard, 1989).
B,

In the case of human cathepsin

alternative splicing at the 5'

end is not due to the
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selection of a variant consensus sequence at the 5' and 3 1
splicing sites, as discussed above.
Regulation
differences

of

alternative

splicing

also

involves

in cellular trans-acting factors that usually

assemble with the transcript into a splicing complex.

Cases

of alternative splicing , where identical pre-mRNA transcripts
give rise to different mRNAs in a cell-type or developmental
stage-specific manner, clearly demonstrate that the splicing
environment of different cells varies for these transcripts
(Breitbart and Nadal-Ginard, 1987; Wieczorek et al.
The different distributions of variant
resulting

1988).

cathepsin B mRNAs

from alternative splicing in human tissues

and

tumors are more likely due to differences in the cellular
trans-acting

factors

which

are

involved

in

pre-mRNA

processing.
The trans-acting factors which have been identified to be
associated

with

pre-mRNA processing

include

proteins and several other protein factors.
and

us

snRNPs

functional

are

the

components

of

most
the

(Padgett et al.

splicing takes place

characterized
where

1984; Black et al.

1985; Chabot et al.

1985; Black and Steitz,

show

sequence

heterogeneity

pre-mRNA

1983; Krainer et al.

1984; Kramer et al.

snRNAs

hnRNP

Ul, U2, U4/U6,

extensively
spliceosome

snRNP,

1985; Black et al.

(Lund,

1986) .
1988)

and

Some
are

regulated in a developmental and tissue-specific manner (Kato
and Harada, 1985; Lund et al. 1985; Lund and Dahlberg, 1987;
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Fu et al. 1988; Krof et al. 1988).
proteins

indicated

than

these

Some studies of snRNP
could

phosphorylation (Woppman et al. 1988).

be

modified

by

Thus, differentially

modified snRNP protein components, as well as snRNA-sequence
heterogeneity may allow for functionally distinct,
specif ic

or

developmentally

regulated

snRNPs

tissue-

which

could

permit cells to tune the existing splicing machinery and
facilitate differential splice-site utilization.

Alterations

in Ul snRNP levels have also been shown to affect splice site
selection in both artificial and natural pre-mRNAs

(Green,

1991).
In addition to the above snRNPs, several protein factors
have been shown to be required for splicing, such as hnRNP
proteins, Al, A2, Bl, B2, Cl, C2, and D, which were associated
with hnRNA (Dreyfuss, 1986; Chung and Wooley, 1986; Ruby and
Abelson, 1991; Conway et al. 1988; Gil et al. 1991; Patton et

al. 1991), and splicing factor SF2 (Krainer et al. 1990a,b).
Recently, Mayeda and Krainer (1992) reported that hnRNP Al and
splicing

factor

SF2

splicing in vitro.

could

regulate

alternative

pre-mRNA

They demonstrated that changes in the

relative concentrations of SF2 and hnRNP Al could modulate
alternative 5' splice site selection in vitro in some natural
pre-mRNAs,

such

as

the

adenovirus

ElA

pre-mRNA.

These

splicing factors did not appear to operate in a substratespecif ic manner, but rather they had a general effect on the
polarity of alternative 5' splice-site selection.

Thus, an
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excess

of

SF2

over

hnRNP

Al

consistently

resulted

in

activation of proximal 5' splice sites, whereas an excess of
hnRNP Al over SF2 generally favors distal 5' splice sites.

If

regulation of alternative 5' splice-site selection by hnRNPAl
and

SF2

takes

place

in

vivo,

the

concentration

or

the

activities of one or both of these factors is predicted to be
subject to tissue-specific, developmental,
control.

or physiological

Interestingly, the intracellular concentration of

hnRNP Al has been reported to increase in proliferating versus
quiescent cells (Lestourgeon et al. 1977; de Koch et al. 1981;
Celis et al. 1986; Planck et al. 1988).

In addition, specific

transformation-related changes in the alternative splicing
patterns of several cellular genes have been reported (Boris

et al. 1987; Zardi et al. 1987; Goodwin et al. 1991). This
present study also demonstrates that the human cathepsin B
gene can undergo changes in splicing patterns in tumor cells.
These results together with the role of hnRNP Al and SF2 in
the

alternative

splicing

suggested

that

quantitative

differences in hnRNP Al and SF2 might contribute to these
transformation-related changes in gene expression.

The effect

of hnRNP Al and SF2 on the changes of alternative splicing in
human cathepsin B pre-mRNA among different normal tissues and
tumors can be tested by quantification of hnRNP Al and SF2 in
these tissues.
Another possibility for different distribution of variant
human cathepsin B mRNA in normal tissues and tumors may be
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differences in cellular factors which affect stability of the
respective mRNAs.

This alternative hypothesis can also be

tested directly by measuring the rates of decay of the variant
messages.

D.

Comparison of Translational Activities of cathepsin B
mRNAs with variant S'-OTRs

As discussed above, multiple forms of cathepsin B cDNAs
which differ in their lengths of 5 1 -UTRs have been cloned.
The results of RNase protection assays confirmed the presence
of cathepsin B mRNAs with different 5'-UTRs in human normal
tissues and

tumors,

transcripts with

a

and also revealed that the
full

ratio

of

length 5'-UTR to truncated forms

varied widely among normal human tissues, and between normal
tissues and tumors.

Forms containing a

truncated 5 '-UTR

(lacking exon 2) were much more abundant in human tumors than
that in normal tissues.

Many studies have demonstrated that

5'-UTR can affect translational capacity of a transcript. To
investigate the possible role of the 5'-UTR of cathepsin B
transcripts on their translation, the translation efficiencies
of cathepsin B mRNAs differing in their 5'-UTRs were studied
in this present work.

Transcripts lacking exon 2 were twice

as

containing

active

translation

as

those

assay

employing

exon

synthetic

2

in

capped

an

in

RNAs

vitro
and

a

reticulocyte lysate (Figure 19 and 21), suggesting that the in

vitro translation of cathepsin B is under the control of the
5 1 -UTR.

These results together with those from the RNase
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protection assays suggest that alternative splicing of the 5 ' UTR of cathepsin B may play a role in the regulation of
cathepsin B expression.
The mechanisms involved in regulation of translation by
5'-UTR have been studied, and three properties of the 5'-UTR
have been shown to influence the translatability of an mRNA
(Kozak, 1991a,b}: (l} the presence of GC rich sequences which
can modify secondary structure; (2) the presence of short open
reading frames;
(1988}

(3)

the length of the 5'-UTR.

demonstrated that

growth factor 2

(PDGF-2}

effect on translation.
that

is

highly

structures.

GC

5 '-UTR of

Rao et al.

c-sis/platelet-derived

transcript exerted an inhibitory

This transcript contains a long 5 '-UTR
rich

and

can

form

stable

secondary

Deletion of the 5'-UTR resulted in as much as a

10 fold increase in c-sis PDGF-2 expression in vivo.

There is

growing evidence that expression of a gene may be negatively
modulated at

the

translational

structures in the 5'-UTR of mRNA.
the

translation

rate

of

level

by

stable secondary

It has been observed that

ornithine

decarboxylase

mRNA

containing full length 5'-UTR was much lower than that of mRNA
containing no 5' lead sequence in both in vivo and in vitro
assays (Grens and Scheffler, 1990; Manzella and Blackshear,
1990}.

This effect was shown to be due to the GC-rich segment

of the UTR which has the potential to form a very stable
hairpin structure.
5 '-UTR on the

The effect of secondary structure in the

translation of a

transcript

has also

been
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studied by insertion of a synthetic oligonucleotide designed
to create a hairpin structure upstream from the ATG initiation
codon of preproinsulin transcripts (Kozak, 1986; Kozak, 1989).
The results revealed that the hairpin structures in the range
of stability of aG

= -so kcal/mol could reduce the efficiency

of translation 85 to 95%, whereas weaker secondary structures
(aG

= -30 kcal/mol) did not affect the rate of translation.

It was thought that the weaker secondary structure could be
readily melted by functional 40S ribosomal subunits which are
presumed to bind to the capped S' end of an mRNA and migrate
linearly until reaching the first AUG codon where they are
joined by a

60S subunit.

In contrast,

stable secondary

structure could block the migration of the 40S subunits.
Another factor which can affect translational efficiency
is the presence of an open reading frame in the 5'-UTR.

The

occurrence of an upstream AUG start codon which is followed
shortly by a termination codon to create a small open reading
frame at the s•-end of the mRNA nearly always reduces the
efficiency of translation initiation from a downstream AUG
codon.

Impairment of translation by an open reading frame

burdened 5' untranslated leader sequence has been reported for
many mRNAs, such as rat insulin-like growth factor I (Foyt et
al.

1991;

Lowe et al.

1987),

rat

farnesyl

pyrophosphate

synthetase (Teruya et al. 1990), rat thyroid hormone receptor
(Murray et al. 1988), human interleukin-? (Young et al. 1991),
human and mouse interleukin-2 receptor (Weinberg and Swain,
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1990), human fibroblast growth factor-5

(Bares et al. 1991)

and transforming growth factor-P3 (Arrick et al. 1991).

The

simplest explanation is that, after a ribosome translates the
upstream open reading frame , the 405 ribosomal subunit may
reinitiate at another AUG codon downstream.

The inhibitory

effect of the upstream AUG codon may be attributable to the
inefficiency of this reinitiation.

Reinitiation could be

inefficient for a variety reasons.

One possibility is that

ribosomes frequently dissociate from mRNA at the upstream
termination codon.

A related possibility is that ribosomes

remain on the mRNA but are unable to recruit other components
of

translation

downstream

open

initiation
reading

before

frame.

reaching
A

third

the

second

mechanism

of

inhibition can be imagined in which ribosomes become stalled
at the upstream open reading frame, thereby blocking further
scanning downstream (Mueller and Hinnebusch, 1986).
In addition to secondary structures and open reading
frames in the 5 '-UTR, the length of 5 '-UTR has also been shown
to affect the translation of mRNA.

The transcript of the

human complement protein C2 has an unusually long 5 1 -UTR (388
nt).

Deletion

of

this

region

resulted

in

a

10

fold

enhancement in the translational efficiency of C2 in transient
eukaryotic

cellular

assays

(Horiuchi

et

al.

1990).

A

decreased translation rate due to the lengthening of the 5'
noncoding sequence was also found for the genes of murine
tissue inhibitor of metalloproteinases

(Waterhouse et al .
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1990), rat guanylate cyclase {Chinkers et al. 1989) and human

8 globin {Leung et al. 1989).

It has been reported that RNAs

containing a 5'-UTR greater than 200 nt were translated much
less

efficiently

than

their

truncated

counterparts

eukaryotic ribosomes in vitro {Young et al. 1981).

by

Because in

most cases the originally long 5 '-UTRs contain sequences which
can form secondary structures,

there is argument that the

effect of this kind of 5'-UTR on the translation might be due
to

both

length

and

secondary

structure.

Recently

Kozak

{1991c,d) has used synthetic 5' noncoding sequences which were
designed

to

increase

the

length

of

the

5'-UTR

without

introducing secondary structure to study the effect of the
length of 5'-UTR on translation.

In contrast to the negative

effect on translation reported previously,
lengthening the 5'

she found that

noncoding sequence of transcripts could

increase their translational efficiency under conditions of
translation

in

reticulocyte

lysates.

In

these

cases

translation efficiency was proportional to leader length in
the range of 17 to about 80 nucleotide.
long

5'

leader

sequences

appear

to

It seems likely that
accumulate

extra

40S

ribosomal subunits, which may account for their translational
advantage.

However, the effect on translation of inserting

more than 80 nucleotides of synthetic sequence prior to the
AUG codon remains unknown.
The 88 nt exon 2 of human cathepsin B transcripts, which
is sometimes spliced out of the 5'-UTR to generate transcript
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with truncated 5 '-UTR,

has features which can affect the

translation efficiency of the transcript.

It extends the 5'-

UTR to 237 nucleotides for full length 5'-UTR, contains an
adjacent

start

translation

and

start

stop
site

codon
and

is

upstream
GC

from

rich.

In

the

normal

addition,

a

preliminary computer analysis of the secondary structure of
cathepsin B cDNA indicates that there is a potential for
formation of a stable stem-loop structure between part of exon
2

and a

These features may

nearby downstream sequence.

explain the decreased translational activity of the cathepsin
B transcript with the full length 5'-UTR in the in vitro assay
compared to that of the cathepsin B transcript missing exon 2.

E.

Characteristics of cathepsin B Transcript Missing Exons 2
and 3

A significant new finding in this present work is the
detection in human breast and colon carcinomas and in human
melanomas of a fifth type of cathepsin B transcript which
lacks exon 2, noncoding, and exon 3 encoding the 17 residue
signal peptide and 25
(Figure

12,

15,

17,

residues of the
and

24).

I

activation peptide

have

shown

that

this

transcript is complete in that it contains the remainder of
the cathepsin B coding sequence and part of the 3'-UTR which
is common to all full length cathepsin B mRNAs (Figure 17).
I

have

also

demonstrated

by

in

vitro

transcription

and

translation that the corresponding synthetic message-lacking
exons 2 and 3 can be translated, possibly from an in-frame
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internal methionine (residue 52) within the propeptide region.
The resulting 32 KDa protein product (Figure 22) would lack
the signal peptide which is required for directing cathepsin
B to the lysosomes, and the first 34 residues of the 62 amino
acid propeptide which inhibits enzyme activity.

Remarkably,

this RNA is 4 times more active in the reticulocyte lysate
than an RNA lacking exon 2, and 8 times more active than the
RNA

containing

determined

the

that

full

this

length

truncated

5 '-UTR.
product

Furthermore,
can

be

folded

I
to

produce a native structure.
After treatment of an in vitro translation mixture with
decreasing
promote
detected.

concentrations

refolding,

of

cathepsin

guanidinium hydrochloride to
B enzyme

activity

could

be

In contrast, treatment with an "oxide-shuffling"

buff er to promote disulfide bond formation failed to generate
an active enzyme.
is

a

highly

conformation.

The ability to acquire enzymatic activity

stringent

test

of

folding

into

a

native

Results in Figure 22 show that the activity

obtained after dialysis against decreasing concentrations of
guanidinium hydrochloride is easily detected by the standard
cathepsin B assay.

This

demonstrates that the 32,000 dalton

truncated form of cathepsin B can be refolded to produce an
active species, and that the missing propeptide region of this
protein product is not essential for correct folding.

I also

found that treatment of the refolded product with pepsin, to
remove the remainder of the activation propeptide, increased
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its activity three fold. We postulated that either the removal
of the entire activation propeptide may not be necessary for
activation, or some of the enzyme may undergo autolysis during
folding which removed the remainder of the propeptide.
These results indicated that cathepsin B transcripts from
human tumors which lacks exons 2 and 3 are
functional

mRNAs.

Our

ability

to

ref old

likely to be

the

translated

product of the corresponding synthetic mRNA into an active
enzyme in vitro increases the likelihood that such message
would produce a stable, active protein in vivo.

Further, we

can speculate that this molecular form of cathepsin B, missing
the N-terminal signal peptide, may no longer be targeted to
the lysosome.
Cellular transformation and other pathological changes
can be accompanied by a

redistribution of cathepsin B to

secretory vesicles (Docherty et al. 1984; Saluja et al. 1989;
Achkar et al. 1990), the plasma membrane (Pietras and Roberts,
1981; Sloane et al. 1987; Keren and LeGrue, 1988; Weiss et al.
1990)

and

the

nucleus

(Pietras

and

Roberts,

1981).

Transformed cells also contain and secrete several different
molecular forms

of cathepsin B including higher molecular

weight latent and active forms (Recklies et al. 1980; Mort et

al.

1980;

Dufek

et

al.

1984;

Biaci

and

Knopeel,

1986;

Petrova-Skalkova et al. 1987; Keppler et al. 1988b; Docherty
and Phillips, 1988; Maciewicz et al. 1989).

Some of these

undoubtedly reflect alterations in the linked targeting and
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posttranslational processing of the cathepsin B which result
in changes in the amount and composition of oligosaccharide
side chain (Keppler et al. 1988b; Nishimura et al. 1988) and
the extent of proteolytic modifications
Hara et al.

1988).

Our present

(Chan et al. 1986;

results

also

raise

the

possibility that in some human tumors a part of this diversity
of form and location may be due to alternative splicing of
cathepsin B pre-mRNA.

One can speculate that the putative

product of a cathepsin B mRNA missing exon 3 could have a
cytosolic and/or nuclear location and could participate in the
modulation of cellular activity by the limited proteolytic
modification of key regulatory proteins.

Interestingly, it

has recently been shown that the product of the c-Ha ras gene
is structurally homologous to some members of the cystatin
type II gene family, and can bind to cathepsin B and related
enzymes with high affinity (Hiwasa et al. 1987; Rawlings and
Barrett, 1990) .

CHAPTER Vl:

SUMMARY

1.
result

Multiple forms of cathepsin B transcripts,
from

alternative

processing

in

the

5'

which

and

3'

untranslated regions (UTRs), have been identified in normal
human tissues and human tumors by Northern blot and RNase
protection assays.

2.

The relative levels of the cathepsin B transcripts

(2.3 Kb and 4.0 Kb) differing in the lengths of their 3'-UTRs
has been measured in normal human skeletal muscle, kidney,
liver,

spleen

and

colon,

and

in

the

two

variants A375P and A375M by Northern blot.

human melanoma

The ratios of the

2. 3 Kb transcript to the 4. o Kb transcript only varied by
about a factor 2,

from 2. 8 to 6. 2.

Thus, the regulatory

significance of these two cathepsin B mRNA forms is unclear at
present.

3.

The relative levels of the cathepsin B mRNAs which

differ in the lengths of their 5 1 -UTRs were also measured by
RNase protection assays

in normal
124

human skeletal muscle,
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kidney, liver, spleen and colon, in samples from human colon
and breast carcinomas, and in several established cultured
human tumor cell lines, two prostate carcinoma variants, PCJP
and PCJM, two melanoma variants A375P and A375M, and colon
carcinoma.

The ratios of the transcript lacking exon 2 to

that containing exon 2 varied widely from less than 0.1 to 3
for the normal tissues, and from 6.0 to 24 for the tumors and
tumor derived cell lines.
5 '-UTR were much more

Thus, transcripts with the shorter

abundant

in tumors

than

in normal

tissues.

3.

An in vitro transcription/translation assay was used

to demonstrate that the cathepsin B transcripts with variant
5'-UTRs differ in their rates of translation.
rates

are

about

2: 1

for

mRNAs

lacking

exon

The relative
2

to

mRNAs

and

human

containing the full length 5' end.

4.

Human

breast

and

colon

carcinomas

melanomas, A375P and A375M, contain a cathepsin B transcript
which is also missing exon 3 encoding the signal peptide and
7 residues of the activation propeptide.

This transcript is

complete, and contains the remainder of the cathepsin B coding
sequence and part of the J'-UTR which is common to all full
length cathepsin B mRNAs.

5.

An in vitro transcription/translation assay was used
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to demonstrate that cathepsin B transcripts missing exon 3
could be translated from an internal methionine codon (residue
52), producing a 32 KDa product lacking the signal peptide and
more

than half

the

propeptide.

This

truncated

form

of

cathepsin B should no longer be targeted to the lysosome.

6.

Finally, the translation product from the message

missing exons 2 and 3 was able to acquire a
conformation

after

in

refolding

vitro.

native-like

This

refolded,

truncated protein was active against the specific substrate,
N-benzyloxycarbonyl-L-arginyl-L-arginine-7-amido-4methylcoumarin

(Z-Arg-Arg-AMC).

Treatment with pepsin,

to

remove the remainder of the activation propeptide, increases
catalytic

activity

3

fold.

These

results

indicate

that

cathepsin B mRNA lacking exons 2 and 3 is likely to be a
functional mRNA.

These
cathepsin

findings

suggest

B pre-mRNA

may

be

that

alternative

involved

in

splicing

regulating

of
the

expression and subcellular distribution of cathepsin B in
human tissues and tumors.
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